

# Regulation of protein O-GlcNAcylation by circadian, metabolic, and cellular signals

Received for publication, July 24, 2023, and in revised form, December 12, 2023. Published, Papers in Press, December 29, 2023, <https://doi.org/10.1016/j.jbc.2023.105616>

Xianhui Liu<sup>‡</sup>, Yao D. Cai<sup>‡</sup>, and Joanna C. Chiu<sup>\*</sup>

From the Department of Entomology and Nematology, College of Agricultural and Environmental Sciences, University of California, Davis, California, USA

Reviewed by members of the JBC Editorial Board. Edited by Robert Haltiwanger

O-linked  $\beta$ -N-acetylglucosamine (O-GlcNAcylation) is a dynamic post-translational modification that regulates thousands of proteins and almost all cellular processes. Aberrant O-GlcNAcylation has been associated with numerous diseases, including cancer, neurodegenerative diseases, cardiovascular diseases, and type 2 diabetes. O-GlcNAcylation is highly nutrient-sensitive since it is dependent on UDP-GlcNAc, the end product of the hexosamine biosynthetic pathway (HBP). We previously observed daily rhythmicity of protein O-GlcNAcylation in a *Drosophila* model that is sensitive to the timing of food consumption. We showed that the circadian clock is pivotal in regulating daily O-GlcNAcylation rhythms given its control of the feeding-fasting cycle and hence nutrient availability. Interestingly, we reported that the circadian clock also modulates daily O-GlcNAcylation rhythm by regulating molecular mechanisms beyond the regulation of food consumption time. A large body of work now indicates that O-GlcNAcylation is likely a generalized cellular status effector as it responds to various cellular signals and conditions, such as ER stress, apoptosis, and infection. In this review, we summarize the metabolic regulation of protein O-GlcNAcylation through nutrient availability, HBP enzymes, and O-GlcNAc processing enzymes. We discuss the emerging roles of circadian clocks in regulating daily O-GlcNAcylation rhythm. Finally, we provide an overview of other cellular signals or conditions that impact O-GlcNAcylation. Many of these cellular pathways are themselves regulated by the clock and/or metabolism. Our review highlights the importance of maintaining optimal O-GlcNAc rhythm by restricting eating activity to the active period under physiological conditions and provides insights into potential therapeutic targets of O-GlcNAc homeostasis under pathological conditions.

Protein O-linked  $\beta$ -N-acetylglucosamine (O-GlcNAcylation) is a unique type of glycosylation, where N-acetylglucosamine (GlcNAc) dynamically cycles on serine and threonine residues of proteins. Since its first discovery in the 1980s in lymphocytes (1), O-GlcNAcylation has been widely found in over 16,000 proteins to date in all domains of life (2). These O-

GlcNAcylated proteins are involved in a wide range of fundamental biological processes (3–8), including transcription, translation, nutrient sensing, immune response, cell signaling, cell cycle, and circadian clocks. Importantly, aberrant O-GlcNAcylation has become the hallmark of many diseases (5, 9–12), such as cancer, neurodegenerative diseases, cardiovascular diseases, insulin resistance, and type 2 diabetes.

Given the indispensable role of O-GlcNAcylation under both physiological and pathological conditions, it is critical to understand the mechanisms that regulate the cycling of O-GlcNAcylation. O-GlcNAcylation is conventionally considered nutrient-sensitive because it is dependent on the substrate UDP-GlcNAc, the end product of the hexosamine biosynthetic pathway (HBP). HBP is a critical pathway that integrates glucose, amino acid, lipid, and nucleotide metabolism (5). After UDP-GlcNAc is produced, O-GlcNAc transferase (OGT) catalyzes the addition of GlcNAc groups onto proteins, *i.e.* O-GlcNAcylation (13–15), while O-GlcNAcase (OGA) catalyzes the removal of GlcNAc group (16, 17). Indeed, metabolic input determines substrate availability of O-GlcNAcylation (8, 18–21). Decades of investigations also uncovered the regulation of O-GlcNAcylation by metabolic input *via* the modulation of HBP enzymes and O-GlcNAc processing enzymes.

Accumulating evidence showed that many other cellular signals and conditions also contribute to the regulation of protein O-GlcNAcylation. Notably, the circadian clock has been shown to shape the daily rhythm of protein O-GlcNAcylation (18). The circadian clock is an endogenous biochemical timer that allows organisms to anticipate predictable environmental changes over the 24-h day-night cycles, such as daily light-dark cycles and temperature cycles (22–25). In animals, daily oscillations of physiological, metabolic, and behavioral processes are strongly regulated by circadian clocks (22–25). Therefore, the regulation of protein O-GlcNAcylation by circadian clocks could be imposed at multiple levels. At the behavioral level, the circadian clock controls daily feeding-fasting behavior to rhythmically provide metabolic input for UDP-GlcNAc production and O-GlcNAcylation (18). Indeed, under physiological conditions, the daily feeding-fasting cycle is shown to correlate with daily O-GlcNAcylation rhythm in mouse hearts (26) and *Drosophila* tissues (18). At the cellular level, circadian clocks can orchestrate daily rhythms in mRNA,

<sup>‡</sup> These authors contributed equally to this work.

<sup>\*</sup> For correspondence: Joanna C. Chiu, [jcchiu@ucdavis.edu](mailto:jcchiu@ucdavis.edu).

protein abundance, and/or enzymatic activities of HBP enzymes and O-GlcNAc processing enzymes (18, 27–29). Finally, a number of other factors also influence O-GlcNAcylation, such as endoplasmic reticulum (ER) stress, oxidative stress, infection, apoptosis, development, and aging, to name a few (30–40).

In this review, we will provide a broad overview of the metabolic, circadian, and cellular signals that regulate protein O-GlcNAcylation. We will summarize the effect of nutrient availability on HBP and O-GlcNAcylation, highlight the metabolic regulation of protein O-GlcNAcylation through impacting HBP and O-GlcNAc processing enzymes, discuss the evidence on the regulation of daily O-GlcNAcylation rhythms by the circadian clock, and outline other cellular signals that modulate protein O-GlcNAcylation.

### The regulation of protein O-GlcNAcylation by nutrient availability

Depending on the cell type and metabolic status of the cell, 0.003% to 3% of the glucose in cells feeds into the HBP pathway (41–43). In primary cultured adipocytes, Marshall *et al.* (41) indirectly estimated that 2% to 3% of glucose feeds into the HBP by measuring the relative glucosamine *versus* glucose utilization of the cells. Gibb *et al.* (42) concluded that the HBP in cultured neonatal cardiomyocytes utilizes more glucose than the pentose phosphate pathway by measuring the overall levels of isotope-labeled UDP-HexNAc. Their study suggested that previous studies severely underestimated glucose flux into the HBP. Olson *et al.* (43) directly monitored glucose flux through the HBP using isotope tracking in an isolated working mouse heart and observed that only 0.003% to 0.006% of glucose is metabolized through the HBP. Future investigations are warranted to determine the glucose fluxes into the HBP in different cell types, organs, and species and investigate how glucose fluxes are differentially regulated in different cell types and organs.

The HBP then converts metabolites from amino acid, lipid, and nucleotide metabolism to produce UDP-GlcNAc (Fig. 1A). Since the activity of OGT is highly responsive to UDP-GlcNAc concentration with multiple  $K_m$  values (44), the effect of nutrient availability on UDP-GlcNAc level has been of great interest. Generally, UDP-GlcNAc levels in many tissue culture experiments have been observed to change in accordance with the levels of various nutrients, including glucose, glutamine, glucosamine, acetylglucosamine, uridine, palmitate, and stearate (19–21, 45–49) (Fig. 1B). Moreover, the correlation between nutrient availability and UDP-GlcNAc has also been investigated in animals. The UDP-GlcNAc level has been shown to increase in rat skeletal muscles after infusion of lipid emulsion, uridine, or GlcN for 7 h (50). In *Drosophila*, the daily UDP-GlcNAc level correlates with feeding rhythm under *ad libitum* conditions (18). This correlation has been confirmed by time-restricted feeding paradigms. When the fly feeding activity was restricted to different 6-h windows within a day-night cycle, the timing of the peak of the daily UDP-GlcNAc rhythm shifted according to the timing of food consumption.


Experiments to determine whether protein O-GlcNAcylation level corresponds to nutrient availability have produced mixed results so far. In some cell lines or *ex vivo* tissues, O-GlcNAcylation levels increase as the level of glucose, glucosamine, and glutamine increases (51–54) and vice versa (19, 55). Similarly, under pathological conditions, excessive glucose availability during hyperglycemia results in higher O-GlcNAcylation levels (11, 56–58). *In vivo* studies in mouse heart and fly tissues also reported that daily O-GlcNAcylation rhythm is correlated with feeding-fasting cycles and nutrient availability (18, 26). Nevertheless, glucose starvation has been shown to increase O-GlcNAcylation in several studies (19, 59, 60). In addition, when flies are fed at unnatural feeding time (*i.e.* when flies are awake but normally fasting), O-GlcNAcylation rhythm does not shift its peak time to coincide with the shifted time of food consumption, but rather feeding at unnatural time results in dampened O-GlcNAcylation rhythm (18). On one hand, glucose starvation or mistimed eating could modulate OGT, OGA, and glutamine fructose-6-phosphate aminotransferase (GFAT), the rate-limiting enzyme of HBP (See sections below) (19, 59, 60), thus creating more complex scenarios rather strict correlation between nutrient availability and O-GlcNAcylation level. Indeed, mistimed eating alters *ogt* and *oga* mRNA levels, as well as GFAT enzymatic activity (18). On the other hand, it is very likely that the response of protein O-GlcNAcylation to glucose starvation or mistimed eating could be cell type or tissue-specific, as Pham *et al.* (55) demonstrated that nutrient deprivation differentially influences protein O-GlcNAcylation in a number of cell lines.

In conclusion, despite that nutrient availability mostly determines UDP-GlcNAc production in cell lines and tissues, cellular O-GlcNAcylation level does not always correspond to nutrient availability. This suggests that additional cellular factors regulate protein O-GlcNAcylation. Future investigations into conservation and differences in the regulation of UDP-GlcNAc production and O-GlcNAcylation by nutrient availability in different organs and species, especially diurnal *versus* nocturnal animals, will certainly provide new insights into the regulation of protein O-GlcNAcylation by nutrient availability.

### Metabolic regulation of protein O-GlcNAcylation through regulation of HBP enzymes

In addition to nutrient availability, the activity of HBP enzymes also plays critical roles in UDP-GlcNAc production. Four key enzymes are involved in HBP: GFAT, glucosamine-phosphate N-acetyltransferase (GNPNAT), GlcNAc phosphomutase (PGM3/AGM1), and UDP-N-acetylglucosamine pyrophosphorylase (UAP1/AGX1) (Fig. 1A).

As the rate-limiting enzyme of HBP (61), GFAT is the most studied to date. In animals, two GFAT paralogs, GFAT1 and GFAT2, share 75% to 80% amino acid sequence. They are functionally equivalent but distributed in different tissues or cell types (62–64). At the mRNA level, *gfat* is responsive to metabolic signals (Fig. 1B). Many macronutrients stimulate *gfat* mRNA expression, including glucose (65–67), glutamine



**Figure 1. Metabolic regulation of protein O-GlcNAcylation.** A, nutrient input from feeding activity or cell culture media provides essential metabolites for hexosamine biosynthetic pathway (HBP). The end product of HBP, UDP-GlcNAc, is the substrate for protein O-GlcNAcylation. The key enzymes that are under additional metabolic regulation are highlighted in blue circle. B, nutrient level regulates the activities of glutamine:fructose-6-phosphate amidotransferase (GFAT) (13, 44, 54, 60–64, 66–73, 76, 77), N-acetylglucosamine kinase (NAGK) (78), O-GlcNAc transferase (OGT) (13, 14, 55, 79–91) and O-GlcNAcase (OGA) (13). These enzymes represent hubs for metabolic regulation of O-GlcNAcylation. The expression denotes mRNA and/or protein expression of indicated enzymes. Functional groups of each metabolite are color-coded to highlight the processes that contribute to their metabolism. Other metabolites or nutrient status that contribute to protein O-GlcNAcylation are illustrated in brown. O-GlcNAc is depicted as G on protein. AMPK, AMP-activated protein kinase; CaMKII, calcium-calmodulin (CaM)-dependent protein kinase II; GCN2, general control nonderepressible 2; GFAT, glutamine-fructose-6-phosphate aminotransferase; GlcN-6-P, glucosamine-6-phosphate; GlcNAc, N-acetylglucosamine; GlcNAc-1-P, N acetylglucosamine-1-phosphate; GlcNAc-6-P, N-acetylglucosamine-6-phosphate; GNPAT, glucosamine-phosphate N-acetyltransferase; GPI, phosphoglucose isomerase; GSK3β, glycogen synthase kinase-3 β; HK, Hexokinase; Hsp90, Heat shock protein 90; IR, insulin receptor; miRNA, microRNA; mTOR, mechanistic target of rapamycin; NR, nuclear receptor; NR4A1, nuclear subfamily four group A member one; OGA, O-GlcNAcase; OGT, O-GlcNAc transferase; PGM3, phosphoacetylglucosamine mutase; PKA, protein kinase A; PTM, post-translational modification; SFK, Src family kinases, UAP1, UDP-N-acetyl glucosamine pyrophosphorylase one; UDP-GlcNAc, uridine diphosphate N-acetylglucosamine; UTP, uridine triphosphate.

(67), glucosamine (65), palmitate (49, 68), stearate (49), and ceramide (68) (Fig. 1B). The effect of glucose and glutamine on *gfat1* expression is mediated by mTOR2-cMYC axis (67), while nuclear receptor subfamily four group A member 1 (NR4A1) transcription factor can respond to palmitate and ceramide levels to increase *gfat2* mRNA (68). Moreover, glucose and glucosamine can upregulate *gfat* mRNA levels by inhibiting microRNA (miR)-27b-3p (65) (Fig. 1B). In addition to evidence from cell culture experiments described above, we showed that *gfat2* mRNA in fly tissues, but not *gfat1* mRNA, is strongly responsive to nutrient input *via* feeding activity (18). On the contrary, nutrient deprivation also increases *gfat1* mRNA expression. This could be mediated by mTOR2 (69) and/or

general control nonderepressible 2 (GCN2)-activating transcription factor 4 (ATF4) pathways (59) (Fig. 1B). Although these observations are counterintuitive considering the nutrient sensitivity of HBP, the increased *gfat1* expression is speculated to have protective roles upon moderate nutrient deprivation (59, 69). In addition to macronutrients, vitamin D can inhibit *gfat* expression in rat hearts through an unknown mechanism (70) (Fig. 1B).

At the posttranslational level, GFAT is phosphorylated by nutrient-sensing kinases, including AMP-activated protein kinase (AMPK), mTOR complex 2 (mTORC2), and protein kinase A (PKA) (Fig. 1B). AMPK, an energy sensor, phosphorylates GFAT1 at serine 243 (S243) (71, 72). mTORC2 also



phosphorylates S243 in response to glucose and glutamine concentration in cell media (73). Furthermore, nucleoside diphosphate kinase B (NDPKB) counteracts S243 phosphorylation through an unknown mechanism (74). Despite that the kinases involved are characterized, how S243 phosphorylation modulates GFAT activity remains controversial. Moloughney *et al.* (73) reported that S243 phosphorylation increases GFAT1 activity, while Eguchi *et al.* (71) showed that S243 phosphorylation downregulates GFAT1 activity. This could be due to different cell lines utilized in these studies (mouse embryonic fibroblasts and HeLa cells in (73), Chinese hamster ovary cells overexpressing insulin receptors in (71)). Finally, under fasting or starvation conditions, GFAT exhibits lower activity (75, 76), which could be mediated by PKA (75) (Fig. 1B). PKA-directed S205 phosphorylation reduces GFAT1 activity (75, 77). The function of PKA-dependent GFAT1(S235) phosphorylation remains unknown (75). On the contrary, PKA is also shown to increase GFAT activity in two other studies (78, 79). Given that PKA also phosphorylates GFAT2(S202) and increases GFAT2 activity by 2.2-fold (80), increased GFAT2 activity may counteract the PKA-dependent reduction of GFAT1 activity (79). Therefore, the effect of PKA on GFAT activity could exhibit cell type specificity depending on relative expression levels of GFAT1 and GFAT2.

Finally, HBP metabolites can feedback to regulate GFAT activity. In the early 2000s, *in vitro* studies showed that glucosamine-6-phosphate (GlcN-6-P), the immediate product of the GFAT-catalyzed reaction, and UDP-GlcNAc both inhibit GFAT activity (78, 81) (Fig. 1B). Follow-up structural biology analysis showed that UDP-GlcNAc interacts with an interdomain linker to allosterically downregulate GFAT activity (82).

In summary, significant progress has been made to uncover the metabolic regulation of *gfat* mRNA and GFAT protein expression as well as its enzymatic activity. In comparison, studies that examined the metabolic regulation of other HBP enzymes are limited. One recent study revealed that glutamine deprivation increases UDP-GlcNAc levels *via* N-acetylglucosamine kinase (NAGK)-dependent salvage of GlcNAc, another precursor of UDP-GlcNAc (83). Future investigations of other HBP enzymes will be important to provide a comprehensive understanding of the metabolic regulation of protein O-GlcNAcylation.

### **Metabolic regulation of protein O-GlcNAcylation through regulation of O-GlcNAc processing enzymes**

OGT utilizes UDP-GlcNAc to modify proteins, while OGA reverses this modification. In this section, we discuss the mechanistic regulation of OGT and OGA by nutrient availability and nutrient sensing pathways. Nutrient availability and nutrient sensing pathways can regulate OGT protein expression (Fig. 1B). Feeding activity and hence nutrient availability have been shown to regulate daily OGT expression rhythm in *Drosophila* animals (18). When flies are subjected to time-restricted feeding (TRF) at different time windows, robust daily oscillation of OGT protein is observed. The peak time of

OGT protein rhythm coincides well with the timing of food consumption (18). A similar phenomenon has been observed at the *ogt* mRNA level under TRF conditions, except for two minor differences: (a) the amplitude of *ogt* mRNA rhythm remains the same when the timing of food consumption is altered and (b) the peak time of *ogt* mRNA is delayed by a few hours after feeding time (18).

A number of other studies investigated the effect of glucose on OGT expression, producing somewhat contradictory conclusions. Under high glucose conditions, glucose can promote *ogt* mRNA and subsequently protein levels through inhibiting miR-200a/b (84) (Fig. 1B). Interestingly, *ogt* mRNA and OGT protein levels have also been shown to be elevated under glucose deprivation (19, 60), although the mechanism is unknown. More recently, L-carnitine has been shown to regulate *ogt* mRNA expression through the activity of nuclear receptors (85) (Fig. 1B). Finally, it has been reported that mTOR nutrient-sensing pathway can promote OGT protein levels *via* the cMYC-Hsp90 axis (86–88) (Fig. 1B).

Regulation of mRNA and protein levels is not the only mechanism by which O-GlcNAc processing enzymes are regulated by metabolic signals. OGT subcellular localization is modulated by nutrient-sensing pathways to achieve temporal O-GlcNAcylation of proteins in different cellular compartments. OGT contains a nuclear localization sequence (NLS) (residue 451–453). Upon O-GlcNAcylation of OGT(S389), importin  $\alpha 5$  recognizes the NLS and imports OGT into the nucleus (89) (Fig. 1B). Given that O-GlcNAcylation is responsive to metabolic signals as described in previous sections, OGT(S389) O-GlcNAcylation could be one of the mechanisms by which metabolic signals regulate OGT. In addition, in response to the glucose level in cell media, AMPK also modulates the nuclear translocation of OGT by OGT(T444) phosphorylation, probably through importin  $\alpha 5$ -dependent mechanisms (90) (Fig. 1B). Finally, the insulin signaling pathway has been shown to recruit OGT to the cytoplasm (91, 92). Upon insulin stimulation, PI(3,4,5)P3 binds the PIP-binding domain of OGT and promotes cytoplasmic localization (92) (Fig. 1B).

Nutrient-sensitive OGT phosphorylation can directly control its enzymatic activity. Insulin signaling promotes phosphorylation of yet uncharacterized tyrosine residue(s) on OGT, possibly by insulin receptor and/or Src protein-tyrosine kinase (91) (Fig. 1B). Downstream of insulin signaling, glycogen synthase kinase 3 $\beta$  (GSK3 $\beta$ ) phosphorylates OGT(S3/4) (93) (Fig. 1B). Wang *et al.* (94) further showed that inhibiting GSK3 $\beta$  alters OGT substrate selectivity, adding an additional layer of OGT regulation by insulin signaling. During nutrient deprivation, calcium-calmodulin-dependent protein kinase II (CaMKII) phosphorylates OGT(S20) and increases OGT activity (95, 96) (Fig. 1B).


Similar to OGT, OGA protein levels are highly dependent on the timing of food consumption in *Drosophila* animals (18). At the transcript level, *oga* mRNA is rhythmic when flies feed at natural feeding time but not at unnatural feeding time when they are normally fasting (18), indicating *oga*/OGT is regulated by both nutrient input *via* feeding and circadian clocks (see

next section). At present, the molecular mechanisms by which *oga* mRNA and OGA protein are regulated by nutrient availability and/or nutrient sensing pathways are largely unknown. One potential mechanism is that nutrient-sensitive O-GlcNAcylation can modify OGA (97). However the functional outcome of OGA O-GlcNAcylation remains a gap in knowledge. In conclusion, OGT can be regulated by metabolic signals in multiple ways, and more studies are warranted to investigate the metabolic regulation of OGA.

### Regulation of daily protein O-GlcNAcylation rhythm by the circadian clock

Given the nutrient sensitivity of protein O-GlcNAcylation discussed in the previous sections, it is perhaps not surprising that protein O-GlcNAcylation oscillates over the 24-h day-night cycle due to rhythmic feeding-fasting behaviors in animals. Indeed, both mice and flies display daily protein O-GlcNAcylation rhythms, primarily peaking during their feeding windows (18, 26) (Fig. 2). Interestingly, several lines of evidence suggest circadian clocks regulate protein O-GlcNAcylation through other mechanisms in addition to the regulation of rhythmic feeding-fasting behavior. First, when flies are forced to feed at unnatural feeding time, protein O-GlcNAcylation rhythm dampens significantly. This indicates circadian clocks may provide buffering mechanisms that prevent protein O-GlcNAcylation from peaking at nonoptimal time. Second, in flies with defective circadian clocks, protein O-GlcNAcylation rhythm also dampens significantly and the levels remain constant throughout a 24-h period (18). This is not purely due to disrupted feeding-fasting activities, given that restricting the feeding time of clock mutant flies at natural feeding time does not rescue O-GlcNAcylation rhythms. We devote this section to reviewing the evidence on the regulation of daily O-GlcNAcylation rhythm by the circadian clock.

In addition to rhythmic UDP-GlcNAc production driven by clock-controlled feeding activity (18), the activity of HBP enzymes could also be under clock control. Based on publicly available circadian transcriptomic datasets in flies and mice, we found that the transcripts encoding all four HBP enzymes oscillate over a day-night cycle in at least one study (Fig. 2 and Table 1). At the protein level, published proteomic datasets suggest that GFAT, GNPAT, and UAP1 proteins exhibit daily oscillation (Fig. 2 and Table 1). As for the enzymatic activity of HBP enzymes, our recent study reported daily oscillation of GFAT enzymatic activity in wild type (WT) fly tissues, but this rhythmicity is diminished in arrhythmic clock mutant flies (*per<sup>0</sup>*; *period* null mutant fly) (18). Interestingly, restricting food consumption of clock mutant flies at natural feeding time of WT flies failed to rescue rhythmic GFAT enzymatic activity. This suggests that a functional circadian clock is essential to maintain GFAT activity rhythm beyond the regulation of feeding-fasting cycles. Given our observation that the peak of daily GFAT activity rhythm is always fixed right after the natural feeding time window in WT flies, even when flies were fed at unnatural feeding time (18), we



**Figure 2. The circadian clock and metabolic signals from the feeding-fasting cycle shape the daily oscillation of protein O-GlcNAcylation.**

The circadian clock receives environmental signals, such as *light-dark cycles*, and regulates the daily feeding-fasting cycle. Feeding-fasting cycle rhythmically provides nutrient input for the hexosamine biosynthetic pathway (HBP) and contributes to the daily rhythmic production of UDP-GlcNAc and protein O-GlcNAcylation rhythms (18). The circadian clock and feeding-fasting cycle also regulate protein O-GlcNAcylation rhythm by modulating the activity of HBP enzymes (13, 22–24, 93, 94) and O-GlcNAc processing enzymes (13, 23, 24, 88, 93, 95–105). Enzymes under daily rhythmic regulation are annotated with clock cartoons. The expression denotes mRNA and/or protein expression of indicated enzymes. *Solid arrows* indicate evidence from targeted studies of individual proteins, while *dashed arrows* indicate evidence gathered from omics studies. Line color differentiates clock-driven regulation (*blue*) and feeding-driven regulation (*brown*). AMPK and REV-ERB $\alpha$  are potential molecular mediators of clock-driven regulation on GFAT (71, 72, 98) and OGT (99), respectively. AMPK, AMP-activated protein kinase; GFAT, glutamine-fructose-6-phosphate aminotransferase; GNPAT, glucosamine-phosphate N-acetyltransferase; OGA, O-GlcNAcase; OGT, O-GlcNAc transferase; PGM3, phosphoacetylglucosamine mutase; UAP1, UDP-N-acetyl glucosamine pyrophosphorylase one.

concluded that circadian clocks impose a stronger regulation on GFAT activity rhythm as compared to nutrient input (Fig. 2). Clock-controlled GFAT regulation likely happens at posttranscriptional and/or posttranslational levels (18). At present, it remains unknown whether the clock-controlled

**Table 1**  
Circadian regulation of hexosamine biosynthetic pathway and O-GlcNAc cycling enzymes in fly or mouse tissues based on published data

Enzymes	Mouse			Fly			Reference
	Transcripts	Protein	Phospho-peptide	Transcripts	Protein	Reference	
GFAT/GFPT	Cycling in liver, SCN, BAT, kidney, and aorta	Cycling in macrophages	Cycling in liver	Cycling in head and body	Non-cycling in head	(18, 28, 29, 98, 173, 197–202)	
GNPNAT	Cycling in liver	Cycling in macrophages	N/A	Cycling in head	Cycling in head	(27, 29, 197, 202–204)	
PGM3	Cycling in liver, urinary bladder, lung, and AG	Cycling in macrophages	N/A	Non-cycling in head	Cycling in head	(27–29, 197, 199, 202, 205–209)	
UAPI	Cycling in kidney, lung and WAT	Cycling in liver and macrophages	N/A	Non-cycling in head	Cycling in head	(27–29, 197–199, 202, 206, 207, 209, 210)	
OGT	Cycling in liver, SCN and DC	Cycling in macrophages	N/A	Cycling in body	Cycling in body	(18, 27–29, 93, 173, 197, 199, 202, 206, 210–213)	
OGA	Cycling in liver	Cycling in liver and macrophages	N/A	Cycling in head and body	Cycling in head and body	(18, 27–29, 198, 202, 203, 205, 211, 214–216)	

Abbreviations: AG, adrenal gland; BAT, brown adipose tissue; DC, distal colon; GFAT/GFPT, Glutamine–fructose-6-phosphate aminotransferase; GNPAT, Glucosamine-phosphate N-acetyltransferase; N/A, Undetected; OGA, O-GlcNAcase; OGT, O-GlcNAc transferase; PGM3, Phosphoacetylglucosamine mutase; SCN, suprachiasmatic nucleus; UAPI, UDP-N-Acetylglucosamine pyrophosphorylase one; WAT, white adipose tissue.

daily feeding–fasting cycle shapes daily GFAT activity rhythm through metabolic regulations (See previous sections). Intriguingly, phosphoproteomics in mouse liver tissue detected rhythmic GFAT1(S259) phosphorylation over a 24-h period and occupancy of this phosphorylation peaks right after mouse feeding phase (98) (Fig. 2). Mouse GFAT1(S259) is equivalent to human GFAT1(S243), the AMPK-directed phosphorylation with still debatable effects on GFAT1 activity as discussed above. Finally, whether rhythmic GFAT1(S259) phosphorylation leads to rhythmic GFAT activity remains to be investigated.


Other than HBP enzymes, OGT and OGA are also under circadian clock regulation. Combing through published circadian transcriptomic and proteomic datasets, we found that both transcript and protein levels of *oga* and *ogt* are rhythmic in mouse and fly tissues (Fig. 2 and Table 1). In our TRF experiments, the respective mRNA and protein of OGT and OGA are all rhythmic in fly body tissues (18) (Fig. 2). More importantly, the rhythmicity of OGT and OGA protein expression is diminished in arrhythmic clock mutant flies (*per<sup>0</sup>*) even under natural feeding time (18), suggesting the requirement of an intact circadian clock to properly regulate the rhythm of OGT and OGA proteins. Finally, in human hepatoma HepG2 cells, REV-ERB $\alpha$ , a core component of the molecular clock, can bind and stabilize OGT (99) (Fig. 2). As REV-ERB $\alpha$  translocates between nucleus and cytoplasm over a day-night cycle, OGT stability in different cellular compartments can also oscillate (99).

In summary, the expression of HBP enzymes and O-GlcNAc processing enzymes are highly regulated by circadian clocks. The phosphorylation and enzymatic activity of GFAT are also rhythmic over a 24-h period. Therefore, under physiological conditions, it is essential to maintain a proper feeding–fasting cycle as established by circadian clocks to maintain an O-GlcNAcylation homeostasis. The regulation of daily O-GlcNAcylation rhythm by the circadian clock is likely to be more extensive than discussed here. Currently, it is unknown whether other HBP enzymes and O-GlcNAc processing enzymes are also rhythmically phosphorylated or rhythmically modified by other posttranslational modifications (PTMs) and whether the activities of other HBP enzymes and O-GlcNAc processing enzymes oscillate over 24-h day-night cycles.

### A wide range of cellular signals regulate protein O-GlcNAcylation

In addition to metabolic and environmental signals communicated through the circadian clock, protein O-GlcNAcylation is also responsive to various other cellular signals, including ER stress, oxidative stress, infection, apoptosis, and cell division (31–33, 35, 36, 38, 39) (Fig. 3). Significantly, elevated O-GlcNAcylation under many stress conditions facilitates cell survival (31, 32, 36, 39). Cellular signals are known to regulate protein O-GlcNAcylation by modulating the activity of HBP enzymes, specifically GFAT, and O-GlcNAc processing enzymes. In this section, we will





**Figure 3. The regulation of protein O-GlcNAcylation by cellular signals and conditions.** Protein O-GlcNAcylation can respond to a wide range of cellular signals and conditions, mediated by GFAT (61, 106–116, 143), OGT (117–123, 126–136, 139–142, 146, 147) and OGA (117, 124, 125, 137–139, 144). The expression denotes mRNA and/or protein expression of indicated enzymes. Known regulators involved are shown and discussed in the text. BAP1, BRCA1 associated protein-1; CASP3, caspase-3; CEBP $\alpha$ , CCAAT/enhancer-binding protein  $\alpha$ ; ChK1, checkpoint kinase one; circRNA, circular RNA; CUL3, cullin three; E6AP, ubiquitin ligase E6AP; EGF, epidermal growth factor; FAS, fatty acid synthase; FOXA2, forkhead box A2; FOXO1, forkhead box protein O1; HIF1 $\alpha$ , hypoxia-inducible Factor; IL-8, interleukin-8; miRNA, microRNA; NAT10, N-acetyltransferase 10; NE, Norepinephrine; NRF2, nuclear factor E2-related factor-2; OGG1, 8-oxoguanine DNA glycosylase one; PERK, protein kinase R-like ER kinase; RANBP2, RAN-binding protein two; RELA, nuclear factor- $\kappa$ B p65; ROCK2, Rho-associated coiled-coil forming protein kinase two; TG2, transglutaminase two; TGF- $\beta$ , transforming growth factor  $\beta$ ; Xbp1, spliced X-box binding protein one.

discuss the cellular signals and relevant mechanisms that target GFAT, OGT, and OGA to regulate protein O-GlcNAcylation. The examples provided in this section are mostly from mammalian cell culture studies.

Multiple humoral signals, environmental stimuli, and stress conditions influence the expression and PTM of GFAT. Angiotensin II (100), epidermal growth factor (EGF) (66), transforming growth factor  $\beta$  (TGF- $\beta$ ) (101), and interleukin-8 (IL-8) (102) can promote GFAT protein expression *via* yet uncharacterized mechanisms (Fig. 3). Other cellular signals can modify transcription factors that are responsible for *gfat* mRNA expression (103–109) (Fig. 3). For example, hypoxia can stimulate *gfat1* expression through hypoxia inducible factor 1 $\alpha$  (HIF1 $\alpha$ ) (104). Forkhead box A2 (FOXA2) can up-regulate *gfat1* expression during apoptosis (106). Unfolded protein response can trigger the expression of multiple transcripts that encode HBP enzymes through the activity of spliced X-box binding protein 1 (Xbp1s) (103). Finally, infection increases GFAT enzymatic activity by transglutaminase 2 (TG2)-dependent PTM on GFAT (110) (Fig. 3).

OGT protein and enzymatic activity also respond to various stimuli and stress conditions. Oxidative stress (111), virus

infection (112, 113), and cytokinesis (114) have been shown to regulate OGT protein levels (Fig. 3). The E6 protein from human papillomavirus can interact with E6AP E3 ligase to enhance OGT ubiquitination and promote OGT degradation (113) (Fig. 3). During cytokinesis, checkpoint kinase 1 (CHK1) phosphorylates OGT(S20), which stabilizes OGT by decreasing OGT ubiquitination (114) (Fig. 3). Other OGT phosphorylation events have also been reported to regulate OGT activity in response to cellular signals. EGF signaling stimulates OGT(Y976) phosphorylation and alters its substrate selectivity (115) (Fig. 3). Norepinephrine (NE) can promote OGT phosphorylation by protein kinase R-like ER kinase (PERK) and increase OGT activity on casein kinase 2 $\alpha$  (CK2 $\alpha$ ) (116) (Fig. 3). Depolarization of neuronal cells can stimulate OGT activity through CaMKIV-dependent phosphorylation (117) (Fig. 3).

Similar to OGT, OGA is also regulated by a range of cellular conditions. OGA expression and activity have been shown to be responsive to apoptosis (118), oxidative stress (111), and maturation of oocytes (119) (Fig. 3). Apoptosis induces the cleavage of OGA protein by caspase-3 (CASP3), yet interestingly no effect on OGA activity was observed (118) (Fig. 3).

Under oxidative stress, OGA activity is diminished by interacting with fatty acid synthase (FAS) (111) (Fig. 3). During *in vitro* maturation of mouse oocytes, N-acetyltransferase 10 (NAT10) increases OGA protein levels by stabilizing *oga* mRNA via mRNA N<sup>4</sup>-acetylcytidine (ac4C) (119) (Fig. 3).

In addition to cellular signals and conditions described above, GFAT, OGT and OGA are also altered under pathophysiological conditions (120–141) (Fig. 3). The misregulation of O-GlcNAcylation has been of great interest in the study of cancers. For example, several microRNAs (123–130, 135, 140, 141) and a circular RNA (122) are found to negatively regulate OGT activity, while Rho-associated coiled-coil forming protein kinase 2 (ROCK2) (120) and BRCA1 associated protein-1 (BAP1) (121) inhibit OGT ubiquitination and stabilize OGT (Fig. 3). OGA expression could be downregulated by RAN-binding protein 2 (RANBP2), a SUMO E3 ligase, which cause degradation of CCAAT/enhancer-binding protein  $\alpha$  (CEBP $\alpha$ ), a transcription factor of OGA (131) (Fig. 3).

In summary, O-GlcNAcylation is responsive to a wide range of cellular signals and/or conditions, suggesting the role of O-GlcNAcylation as a more generalized cellular status effector. Interestingly, cellular signals and/or conditions mentioned in this section also respond to metabolic and circadian signals, forming an intertwined network of regulation on O-GlcNAcylation (Table 2). Given the ubiquitous function of O-GlcNAcylation in biological processes and the importance of

maintaining O-GlcNAcylation homeostasis, it is worth noting that OGT and OGA levels generally correlate with each other in many different cell types or conditions (18, 60, 132, 133, 142, 143). Also, general cellular O-GlcNAcylation status can feedback to regulate OGT and/or OGA expression (134, 144, 145). The detailed molecular mechanism that maintains cellular O-GlcNAcylation homeostasis has been summarized in other review articles (5, 6).

## Conclusion and future prospects

Over 3 decades of investigations have advanced our understanding of the functions of O-GlcNAcylation in various fundamental cellular processes and pathological development of many diseases (5, 9–12). Many studies have shown that O-GlcNAcylation is regulated by nutrient availability and nutrient sensing pathways (Fig. 1). In addition, there is rapidly accumulating evidence indicating that many other cellular signals and molecular pathways modulate protein O-GlcNAcylation (Figs. 2 and 3), suggesting the role of O-GlcNAcylation as a generalized cellular status effector. In this review, we discuss the metabolic regulation of protein O-GlcNAcylation through HBP and O-GlcNAc processing enzymes, summarize the mechanisms by which circadian clocks shape daily O-GlcNAcylation rhythms, and highlight other cellular signals and associated molecular mechanisms that influence cellular O-GlcNAcylation level. Our review emphasizes the importance of maintaining proper daily O-GlcNAcylation rhythm by controlling mealtime. O-GlcNAcylation is tightly regulated by daily nutrient input and circadian clocks and is expected to provide time-of-day specific regulation on cellular processes to mediate clock and metabolic control of daily rhythmic physiology and behavior (8). This review also provides insights into potential targets for the development of therapeutics to alleviate disruption of O-GlcNAc homeostasis in metabolic diseases. As metabolic input is the primary regulatory factor for O-GlcNAcylation, we propose that O-GlcNAcylation could partially mediate the beneficial effects of time-restricted eating in patients with metabolic syndrome, which limits the eating time to under 10 h during the active period (146). Notably, many regulatory factors of O-GlcNAcylation described in this review, such as ROCK2 and BAP1, have been already used as therapeutic targets in patients (147, 148).

In this review, we largely focused on the cellular signals and pathways that regulate overall protein O-GlcNAcylation. Besides the gaps in knowledge we have already highlighted in the previous sections, there remain many questions regarding the regulation of O-GlcNAcylation that warrant future investigations. One interesting question is how OGT and OGA achieve substrate specificity (149, 150), given there are thousands of protein substrates for O-GlcNAcylation. So far, it has been uncovered that mechanisms underlying substrate specificity include phosphorylation (94, 115, 151), subcellular localization (89, 90, 92), dimerization (152–154), structural divergence (111, 155–161), and adaptor proteins (6, 162–166). Another interesting question is how do other PTMs on target proteins, such as phosphorylation (167), acetylation (168–170),

**Table 2**  
Some cellular signals that regulate protein O-GlcNAcylation are themselves under circadian and/or metabolic regulation

Cellular signals	Enzymes that regulate protein O-GlcNAcylation	Under circadian control?	Under metabolic control?
ER stress	Xbp1s	(217)	(218)
TGF- $\beta$		(184, 185)	(219–222)
IL-8		(223)	(224, 225)
Angiotensin II		(180, 181)	(226)
Apoptosis	FOXA2	-	(227)
	CASP3	(228)	(229)
Oxidative stress	FAS	-	(230, 231)
Maturation of oocyte	NAT10	-	-
Cancer or other metabolic diseases	RANBP2-CEBP $\alpha$	(98)	-
	ROCK2	(232)	(233)
	BAP1	-	-
	CUL3-NRF2	(234)	-
	miRNA	(235)	(236)
	circRNA	-	-
Cytokinesis	Chk1	(237, 238)	-
Depolarization	CaMKIV	-	-
Norepinephrine	PERK	(239)	(240, 241)
EGF		(182, 183)	-
Infection	RELA-OGG1	(242)	(243, 244)
	FOXO1	-	(245)
	TG2	-	-
	E6AP	-	(246)
Hypoxia	HIF1 $\alpha$	(247–251)	(252)

Abbreviations: BAP1, BRCA1 associated protein-1; CASP3, caspase-3; CEBP $\alpha$ , CCAAT/enhancer-binding protein  $\alpha$ ; Chk1, checkpoint kinase one; circRNA, circular RNA; CUL3, cullin three; E6AP, ubiquitin ligase E6AP; EGF, epidermal growth factor; FAS, fatty acid synthase; FOXA2, forkhead box A2; FOXO1, forkhead box protein O1; HIF1 $\alpha$ , hypoxia inducible factor 1 $\alpha$ ; IL-8, interleukin-8; miRNA, microRNA; NAT10, N-acetyltransferase 10; NRF2, nuclear factor E2-related factor-2; OGG1, 8-oxoguanine DNA glycosylase one; PERK, Protein Kinase RNA-like ER kinase; RANBP2, RAN-binding protein two; RELA, nuclear factor- $\kappa$ B p65; ROCK2, Rho-associated coiled-coil forming protein kinase two; TG2, transglutaminase two; TGF- $\beta$ , transforming growth factor  $\beta$ ; Xbp1, spliced X-box binding protein one.



and ubiquitination (171–173) interact with O-GlcNAcylation in individual proteins to regulate structure and function. Among these PTMs, phosphorylation is the most well-studied PTM that can facilitate or inhibit protein O-GlcNAcylation depending on the position of amino acid residues (167, 174–176). Future studies examining the interactions between O-GlcNAcylation and other PTMs in response to metabolic and cellular signals are critical to provide a comprehensive understanding of the regulation of biological processes *via* multiple PTMs.

Beyond the cellular level, there have been more and more studies that investigated the impact of environmental, physiological, and systemic changes on protein O-GlcNAcylation in whole animal models. Development (30), aging (37), maternal stress (34), exercise (40, 141, 143, 177), cold exposure (116), fear conditioning (178) and rapid eye movement (REM) sleep deprivation (179) are all shown to influence protein O-GlcNAcylation. However, our knowledge of the underlying mechanisms is rather limited. In mouse skeletal muscle, exercise-induced lactate and hypoxia can signal to HIF1 $\alpha$ , which increases OGT expression and O-GlcNAcylation (141). In mouse brown adipose tissue, cold exposure can trigger OGT phosphorylation by PERK and promote OGT activity (116). Perhaps not surprisingly, the O-GlcNAcylation response appears to be tissue-specific. For example, exercise upregulates O-GlcNAcylation in skeletal muscle (141, 177), but downregulates it in the heart (143). Therefore, more studies are warranted to investigate the mechanisms of O-GlcNAcylation regulation by various physiological and environmental conditions in animal models.

Finally, although the circadian clock has been shown to regulate daily O-GlcNAcylation rhythm (18, 26), the molecular mediator(s) are just starting to be explored (Fig. 2). Many regulators of O-GlcNAcylation mentioned in this review are under clock control, including angiotensin II (180, 181), EGF (182, 183), and TGF- $\beta$  (184, 185) (Table 2). Many of them could play important roles in regulating rhythmic O-GlcNAcylation to control daily biological rhythms. It is important to point out that the daily O-GlcNAcylation rhythm is likely to be different in diurnal *versus* nocturnal animals, given their distinct feeding windows. In the same species, O-GlcNAcylation rhythm and its response to nutrient availability may display organ specificity, due to distinct nutrient sensitivity and metabolic properties of individual organs. For example, the blood-brain barrier renders the brain tissue less sensitive to the fluctuation of nutrients in peripheries, while the heart is extremely metabolically active so that it might be highly impacted by daily feeding activity. It is also interesting to investigate the impact of metabolic diseases on daily O-GlcNAcylation rhythm. As metabolic diseases, or even high-fat diet, are known to disrupt daily rhythms in the transcriptome, sleep/wake cycle, and feeding/fasting cycle (186–191), O-GlcNAcylation might mediate the disruptive effect of metabolic diseases on circadian physiology. Finally, to characterize the function of O-GlcNAcylation in circadian physiology, it is critical to identify the proteins that are

rhythmically modified by O-GlcNAcylation using proteomic approaches. Comparative O-GlcNAcylation is warranted to reveal tissue-specific and/or pathologically disrupted rhythm of O-GlcNAc proteins. Additionally, since phosphorylation (29, 98, 192, 193), acetylation (194, 195), and ubiquitination (196) has been shown to oscillate over a 24-h period at the proteome level, proteome-wide interaction between rhythmic O-GlcNAcylation and other PTMs will also shed light on the regulation of O-GlcNAcylation rhythm on individual proteins.

**Acknowledgments**—This work is supported by NIH R01 DK124068 and R56 DK124068 to J. C. C. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Author contributions**—X. L., Y. D. C., and J. C. C. conceptualization; X. L. and Y. D. C. writing—original draft; X. L., Y. D. C., and J. C. C. writing—reviewing and editing.

**Conflict of interest**—The authors declare that they have no conflicts of interest with the contents of this article.

**Abbreviations**—The abbreviations used are: AMPK, AMP-activated protein kinase; CaMKII, calcium-calmodulin (CaM)-dependent protein kinase II; GCN2, general control nonderepressible 2; GFAT, glutamine-fructose-6-phosphate aminotransferase; GlcN-6-P, glucosamine-6-phosphate; GlcNAc, N-acetylglucosamine; GlcNAc-1-P, N acetylglucosamine-1-phosphate; GlcNAc-6-P, N-acetylglucosamine-6-phosphate; GNPAT, glucosamine-phosphate N-acetyltransferase; GPI, phosphoglucose isomerase; GSK3 $\beta$ , glycogen synthase kinase-3  $\beta$ ; HBP, hexosamine biosynthetic pathway; HK, Hexokinase; Hsp90, Heat shock protein 90; IR, insulin receptor; miRNA, microRNA; mTOR, mechanistic target of rapamycin; NR, nuclear receptor; NR4A1, nuclear subfamily four group A member one; OGA, O-GlcNAcase; O-GlcNAcylation, O-linked  $\beta$ -N-acetylglucosamine; OGT, O-GlcNAc transferase; PGM3, phosphoacetylglucosamine mutase; PKA, protein kinase A; PTM, post-translational modification; SFK, Src family kinases; UAP1, UDP-N-acetyl glucosamine pyrophosphorylase one; UDP-GlcNAc, uridine diphosphate N-acetylglucosamine; UTP, uridine triphosphate.

## References

- Torres, C. R., and Hart, G. W. (1984) Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. *J. Biol. Chem.* **259**, 3308–3317
- Wulff-Fuentes, E., Berendt, R. R., Massman, L., Danner, L., Malard, F., Vora, J., et al. (2021) The human O-GlcNAcome database and meta-analysis. *Sci. Data* **8**, 25
- Hart, G. W. (2019) Nutrient regulation of signaling and transcription. *J. Biol. Chem.* **294**, 2211–2231
- Wang, Y., Fang, X., Wang, S., Wang, B., Chu, F., Tian, Z., et al. (2023) The role of O-GlcNAcylation in innate immunity and inflammation. *J. Mol. Cell Biol.* **14**, mjac065
- Chatham, J. C., Zhang, J., and Wende, A. R. (2021) Role of O-linked N-acetylglucosamine protein modification in cellular (patho)physiology. *Physiol. Rev.* **101**, 427–493
- Yang, X., and Qian, K. (2017) Protein O-GlcNAcylation: emerging mechanisms and functions. *Nat. Rev. Mol. Cell Biol.* **18**, 452–465
- Tan, E. P., Duncan, F. E., and Slawson, C. (2017) The sweet side of the cell cycle. *Biochem. Soc. Trans.* **45**, 313–322

8. Liu, X., and Chiu, J. C. (2022) Nutrient-sensitive protein O-GlcNAcylation shapes daily biological rhythms. *Open Biol.* **12**, 220215
9. Wenzel, D. M., and Olivier-Van Stichelen, S. (2022) The O-GlcNAc cycling in neurodevelopment and associated diseases. *Biochem. Soc. Trans.* **50**, 1693–1702
10. Ciraku, L., Esquea, E. M., and Reginato, M. J. (2022) O-GlcNAcylation regulation of cellular signaling in cancer. *Cell. Signal.* **90**, 110201
11. Bolanle, I. O., and Palmer, T. M. (2022) Targeting protein O-GlcNAcylation, a link between type 2 diabetes mellitus and inflammatory disease. *Cells* **11**, 705
12. Wang, H.-F., Wang, Y.-X., Zhou, Y.-P., Wei, Y.-P., Yan, Y., Zhang, Z.-J., et al. (2023) Protein O-GlcNAcylation in cardiovascular diseases. *Acta Pharmacol. Sin.* **44**, 8–18
13. Haltiwanger, R. S., Holt, G. D., and Hart, G. W. (1990) Enzymatic addition of O-GlcNAc to nuclear and cytoplasmic proteins. Identification of a uridine diphospho-N-acetylglucosamine:peptide beta-N-acetylglucosaminyltransferase. *J. Biol. Chem.* **265**, 2563–2568
14. Haltiwanger, R. S., Blomberg, M. A., and Hart, G. W. (1992) Glycosylation of nuclear and cytoplasmic proteins. Purification and characterization of a uridine diphospho-N-acetylglucosamine:polypeptide beta-N-acetylglucosaminyltransferase. *J. Biol. Chem.* **267**, 9005–9013
15. Kreppel, L. K., Blomberg, M. A., and Hart, G. W. (1997) Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. *J. Biol. Chem.* **272**, 9308–9315
16. Dong, D. L., and Hart, G. W. (1994) Purification and characterization of an O-GlcNAc selective N-acetyl-beta-D-glucosaminidase from rat spleen cytosol. *J. Biol. Chem.* **269**, 19321–19330
17. Gao, Y., Wells, L., Comer, F. I., Parker, G. J., and Hart, G. W. (2001) Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain. *J. Biol. Chem.* **276**, 9838–9845
18. Liu, X., Blaženović, I., Contreras, A. J., Pham, T. M., Tabuloc, C. A., Li, Y. H., et al. (2021) Hexosamine biosynthetic pathway and O-GlcNAc-processing enzymes regulate daily rhythms in protein O-GlcNAcylation. *Nat. Commun.* **12**, 4173
19. Taylor, R. P., Geisler, T. S., Chambers, J. H., and McClain, D. A. (2009) Up-regulation of O-GlcNAc transferase with glucose deprivation in HepG2 cells is mediated by decreased hexosamine pathway flux. *J. Biol. Chem.* **284**, 3425–3432
20. Wellen, K. E., Lu, C., Mancuso, A., Lemons, J. M. S., Ryzcko, M., Dennis, J. W., et al. (2010) The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. *Genes Dev.* **24**, 2784–2799
21. Swamy, M., Pathak, S., Grzes, K. M., Damerow, S., Sinclair, L. V., van Aalten, D. M. F., et al. (2016) Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy. *Nat. Immunol.* **17**, 712–720
22. Longo, V. D., and Panda, S. (2016) Fasting, circadian rhythms, and time-restricted feeding in Healthy Lifespan. *Cell Metab.* **23**, 1048–1059
23. Finger, A.-M., Dibner, C., and Kramer, A. (2020) Coupled network of the circadian clocks: a driving force of rhythmic physiology. *FEBS Lett.* **594**, 2734–2769
24. Dubowy, C., and Sehgal, A. (2017) Circadian rhythms and sleep in *Drosophila melanogaster*. *Genetics* **205**, 1373–1397
25. Patke, A., Young, M. W., and Axelrod, S. (2020) Molecular mechanisms and physiological importance of circadian rhythms. *Nat. Rev. Mol. Cell Biol.* **21**, 67–84
26. Durgan, D. J., Pat, B. M., Laczy, B., Bradley, J. A., Tsai, J.-Y., Grenett, M. H., et al. (2011) O-GlcNAcylation, novel post-translational modification linking myocardial metabolism and cardiomyocyte circadian clock. *J. Biol. Chem.* **286**, 44606–44619
27. Li, X., Shi, L., Zhang, K., Wei, W., Liu, Q., Mao, F., et al. (2018) CirGRDB: a database for the genome-wide deciphering circadian genes and regulators. *Nucleic Acids Res.* **46**, D64–D70
28. Rodriguez, J., Tang, C.-H. A., Khodor, Y. L., Vodala, S., Menet, J. S., and Rosbash, M. (2013) Nascent-Seq analysis of *Drosophila* cycling gene expression. *Proc. Natl. Acad. Sci. U. S. A.* **110**, E275–E284
29. Wang, C., Shui, K., Ma, S., Lin, S., Zhang, Y., Wen, B., et al. (2020) Integrated omics in *Drosophila* uncover a circadian kinase. *Nat. Commun.* **11**, 2710
30. Lefebvre, T., Baert, F., Bodart, J.-F., Flament, S., Michalski, J.-C., and Vilain, J.-P. (2004) Modulation of O-GlcNAc glycosylation during *Xenopus* oocyte maturation. *J. Cell. Biochem.* **93**, 999–1010
31. Zachara, N. E., Molina, H., Wong, K. Y., Pandey, A., and Hart, G. W. (2011) The dynamic stress-induced “O-GlcNAc-ome” highlights functions for O-GlcNAc in regulating DNA damage/repair and other cellular pathways. *Amino Acids* **40**, 793–808
32. Zachara, N. E., O'Donnell, N., Cheung, W. D., Mercer, J. J., Marth, J. D., and Hart, G. W. (2004) Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress: a survival response OF mammalian cells. *J. Biol. Chem.* **279**, 30133–30142
33. Drougat, L., Olivier-Van Stichelen, S., Mortuaire, M., Foulquier, F., Lacoste, A.-S., Michalski, J.-C., et al. (2012) Characterization of O-GlcNAc cycling and proteomic identification of differentially O-GlcNAcylated proteins during G1/S transition. *Biochim. Biophys. Acta* **1820**, 1839–1848
34. Howerton, C. L., Morgan, C. P., Fischer, D. B., and Bale, T. L. (2013) O-GlcNAc transferase (OGT) as a placental biomarker of maternal stress and reprogramming of CNS gene transcription in development. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 5169–5174
35. Liu, Y., Yao, R.-Z., Lian, S., Liu, P., Hu, Y.-J., Shi, H.-Z., et al. (2021) O-GlcNAcylation: the “stress and nutrition receptor” in cell stress response. *Cell Stress Chaperones* **26**, 297–309
36. Groves, J. A., Lee, A., Yildirim, G., and Zachara, N. E. (2013) Dynamic O-GlcNAcylation and its roles in the cellular stress response and homeostasis. *Cell Stress Chaperones* **18**, 535–558
37. Fülöp, N., Feng, W., Xing, D., He, K., Nöt, L. G., Brocks, C. A., et al. (2008) Aging leads to increased levels of protein O-linked N-acetylglucosamine in heart, aorta, brain and skeletal muscle in Brown-Norway rats. *Biogerontology* **9**, 139–151
38. Collins, H. E., and Chatham, J. C. (2020) Regulation of cardiac O-GlcNAcylation: more than just nutrient availability. *Biochim. Biophys. Acta Mol. Basis Dis.* **1866**, 165712
39. Ngoh, G. A., Watson, L. J., Facundo, H. T., and Jones, S. P. (2011) Augmented O-GlcNAc signaling attenuates oxidative stress and calcium overload in cardiomyocytes. *Amino Acids* **40**, 895–911
40. Cox, E. J., and Marsh, S. A. (2013) Exercise and diabetes have opposite effects on the assembly and O-GlcNAc modification of the mSin3A/HDAC1/2 complex in the heart. *Cardiovasc. Diabetol.* **12**, 101
41. Marshall, S., Bacote, V., and Traxinger, R. R. (1991) Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. *J. Biol. Chem.* **266**, 4706–4712
42. Gibb, A. A., Lorkiewicz, P. K., Zheng, Y.-T., Zhang, X., Bhatnagar, A., Jones, S. P., et al. (2017) Integration of flux measurements to resolve changes in anabolic and catabolic metabolism in cardiac myocytes. *Biochem. J.* **474**, 2785–2801
43. Olson, A. K., Bouchard, B., Zhu, W. Z., Chatham, J. C., and Des Rosiers, C. (2020) First characterization of glucose flux through the hexosamine biosynthesis pathway (HBP) in ex vivo mouse heart. *J. Biol. Chem.* **295**, 2018–2033
44. Kreppel, L. K., and Hart, G. W. (1999) Regulation of a cytosolic and nuclear O-GlcNAc transferase. *J. Biol. Chem.* **274**, 32015–32022
45. Nakajima, K., Kitazume, S., Angata, T., Fujinawa, R., Ohtsubo, K., Miyoshi, E., et al. (2010) Simultaneous determination of nucleotide sugars with ion-pair reversed-phase HPLC. *Glycobiology* **20**, 865–871
46. Abdel Rahman, A. M., Ryzcko, M., Pawling, J., and Dennis, J. W. (2013) Probing the hexosamine biosynthetic pathway in human tumor cells by multitargeted tandem mass spectrometry. *ACS Chem. Biol.* **8**, 2053–2062
47. Marshall, S., Nadeau, O., and Yamasaki, K. (2004) Dynamic actions of glucose and glucosamine on hexosamine biosynthesis in isolated adipocytes. *J. Biol. Chem.* **279**, 35313–35319

48. Grigorian, A., and Lee, S.-U. (2007) Control of T cell-mediated autoimmunity by metabolite flux to N-glycan biosynthesis. *J. Biol. Chem.* **282**, 20027–20035
49. Weigert, C., Klopfer, K., Kausch, C., Brodbeck, K., Stumvoll, M., Häring, H. U., *et al.* (2003) Palmitate-induced activation of the hexosamine pathway in human Myotubes. *Diabetes* **52**, 650–656
50. Hawkins, M., Barzilai, N., Liu, R., Hu, M., Chen, W., and Rossetti, L. (1997) Role of the glucosamine pathway in fat-induced insulin resistance. *J. Clin. Invest.* **99**, 2173–2182
51. Liu, J., Marchase, R. B., and Chatham, J. C. (2007) Glutamine-induced protection of isolated rat heart from ischemia/reperfusion injury is mediated via the hexosamine biosynthesis pathway and increased protein O-GlcNAc levels. *J. Mol. Cell. Cardiol.* **42**, 177–185
52. Vasconcelos-dos-Santos, A., Loponte, H. F. B. R., Mantuano, N. R., Oliveira, I. A., de Paula, I. F., Teixeira, L. K., *et al.* (2017) Hyperglycemia exacerbates colon cancer malignancy through hexosamine biosynthetic pathway. *Oncogenesis* **6**, e306
53. Palorini, R., Cammarata, F. P., Balestrieri, C., Monestiroli, A., Vasso, M., Gelfi, C., *et al.* (2013) Glucose starvation induces cell death in K-ras-transformed cells by interfering with the hexosamine biosynthesis pathway and activating the unfolded protein response. *Cell Death Dis.* **4**, e732
54. Hamiel, C. R., Pinto, S., Hau, A., and Wischmeyer, P. E. (2009) Glutamine enhances heat shock protein 70 expression via increased hexosamine biosynthetic pathway activity. *Am. J. Physiol. Cell Physiol.* **297**, C1509–C1519
55. Pham, L. V., Bryant, J. L., Mendez, R., Chen, J., Tamayo, A. T., Xu-Monette, Z. Y., *et al.* (2016) Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma. *Oncotarget* **7**, 80599–80611
56. Chomphoo, S., Kunprom, W., Thithuan, K., Sorin, S., Khawkhaw, K., Kamkaew, A., *et al.* (2023) Hyperglycemia alters O-GlcNAcylation Patterns of hepatocytes in mice treated with Hepatocarcinogen. *In Vivo* **37**, 685–695
57. Oliveri, L. M., Buzaleh, A. M., and Gerez, E. N. (2021) An increase in O-GlcNAcylation of Sp1 down-regulates the gene expression of pi class glutathione S-transferase in diabetic mice. *Biochem. Biophys. Res. Rep.* **27**, 101049
58. Chen, X., Zhang, L., He, H., Sun, Y., Shen, Q., and Shi, L. (2020) Increased O-GlcNAcylation induces myocardial hypertrophy. *In Vitro Cell. Dev. Biol. Anim.* **56**, 735–743
59. Chaveroux, C., Sarcinelli, C., Barbet, V., Belfeki, S., Barthelax, A., Ferraro-Peyret, C., *et al.* (2016) Nutrient shortage triggers the hexosamine biosynthetic pathway via the GCN2-ATF4 signalling pathway. *Sci. Rep.* **6**, 27278
60. Zou, L., Zhu-Mauldin, X., Marchase, R. B., Paterson, A. J., Liu, J., Yang, Q., *et al.* (2012) Glucose deprivation-induced increase in protein O-GlcNAcylation in cardiomyocytes is calcium-dependent. *J. Biol. Chem.* **287**, 34419–34431
61. Paneque, A., Fortus, H., Zheng, J., Werlen, G., and Jacinto, E. (2023) The hexosamine biosynthesis pathway: regulation and function. *Genes (Basel)* **14**, 933
62. Oki, T., Yamazaki, K., Kuromitsu, J., Okada, M., and Tanaka, I. (1999) cDNA cloning and mapping of a novel subtype of glutamine:fructose-6-phosphate amidotransferase (GFAT2) in human and mouse. *Genomics* **57**, 227–234
63. Yamazaki, K. (2014) Glutamine–Fructose-6-Phosphate Transaminase 1, 2 (GFPT1,2). In: Taniguchi, N., Honke, K., Fukuda, M., Narimatsu, H., Yamaguchi, Y., Angata, T., eds. *Handbook of Glycosyltransferases and Related Genes*, Springer, Japan, Tokyo: 1465–1479
64. Nabeebaccus, A. A., Verma, S., Zoccarato, A., Emanuelli, G., Santos, C. X., Streckfuss-Bömeke, K., *et al.* (2021) Cardiomyocyte protein O-GlcNAcylation is regulated by GFAT1 not GFAT2. *Biochem. Biophys. Res. Commun.* **583**, 121–127
65. Zheng, H., Huang, J., Zhang, M., Zhao, H.-J., Chen, P., and Zeng, Z.-H. (2022) miR-27b-3p Improved high glucose-induced Spermatogenic cell damage via regulating Gfpt1/HBP signaling. *Eur. Surg. Res.* **63**, 64–76
66. Paterson, A. J., and Kudlow, J. E. (1995) Regulation of glutamine:fructose-6-phosphate amidotransferase gene transcription by epidermal growth factor and glucose. *Endocrinology* **136**, 2809–2816
67. Liu, B., Huang, Z.-B., Chen, X., See, Y.-X., Chen, Z.-K., and Yao, H.-K. (2019) Mammalian target of rapamycin 2 (MTOR2) and C-MYC modulate glucosamine-6-phosphate synthesis in glioblastoma (GBM) cells through glutamine: fructose-6-phosphate aminotransferase 1 (GFAT1). *Cell. Mol. Neurobiol.* **39**, 415–434
68. Dai, W., Dierschke, S. K., Toro, A. L., and Dennis, M. D. (2018) Consumption of a high fat diet promotes protein O-GlcNAcylation in mouse retina via NR4A1-dependent GFAT2 expression. *Biochim. Biophys. Acta Mol. Basis Dis.* **1864**, 3568–3576
69. Moloughney, J. G., Kim, P. K., Vega-Cotto, N. M., Wu, C.-C., Zhang, S., Adlam, M., *et al.* (2016) mTORC2 responds to glutamine catabolite levels to modulate the hexosamine biosynthesis enzyme GFAT1. *Mol. Cell* **63**, 811–826
70. Derakhshanian, H., Djazayeri, A., Javanbakht, M. H., Eshraghian, M. R., Mirshafiey, A., Jahanabadi, S., *et al.* (2019) Vitamin D downregulates key genes of diabetes complications in cardiomyocyte. *J. Cell. Physiol.* **234**, 21352–21358
71. Eguchi, S., Oshiro, N., Miyamoto, T., Yoshino, K., Okamoto, S., Ono, T., *et al.* (2009) AMP-activated protein kinase phosphorylates glutamine: fructose-6-phosphate amidotransferase 1 at Ser243 to modulate its enzymatic activity. *Genes Cells* **14**, 179–189
72. Zibrova, D., Vandermoere, F., Göransson, O., Peggie, M., Mariño, K. V., Knierim, A., *et al.* (2017) GFAT1 phosphorylation by AMPK promotes VEGF-induced angiogenesis. *Biochem. J.* **474**, 983–1001
73. Moloughney, J. G., Vega-Cotto, N. M., Liu, S., Patel, C., Kim, P. K., Wu, C., *et al.* (2018) mTORC2 modulates the amplitude and duration of GFAT1 Ser-243 phosphorylation to maintain flux through the hexosamine pathway during starvation. *J. Biol. Chem.* **293**, 16464–16478
74. Chatterjee, A., Eshwaran, R., Poschet, G., Lomada, S., Halawa, M., Wilhelm, K., *et al.* (2020) Involvement of NDKP-B in glucose metabolism-mediated endothelial damage via activation of the hexosamine biosynthesis pathway and suppression of O-GlcNAcase activity. *Cells* **9**, 2324
75. Chang, Q., Su, K., Baker, J. R., Yang, X., Paterson, A. J., and Kudlow, J. E. (2000) Phosphorylation of human glutamine:fructose-6-phosphate amidotransferase by cAMP-dependent protein kinase at serine 205 blocks the enzyme activity. *J. Biol. Chem.* **275**, 21981–21987
76. Nelson, B. A., Robinson, K. A., Koning, J. S., and Buse, M. G. (1997) Effects of exercise and feeding on the hexosamine biosynthetic pathway in rat skeletal muscle. *Am. J. Physiol.* **272**, E848–E855
77. Ruegenberg, S., Mayr, F. A. M. C., Atanassov, I., Baumann, U., and Denzel, M. S. (2021) Protein kinase a controls the hexosamine pathway by tuning the feedback inhibition of GFAT-1. *Nat. Commun.* **12**, 2176
78. Graack, H. R., Cinque, U., and Kress, H. (2001) Functional regulation of glutamine:fructose-6-phosphate aminotransferase 1 (GFAT1) of *Drosophila melanogaster* in a UDP-N-acetylglucosamine and cAMP-dependent manner. *Biochem. J.* **360**, 401–412
79. Zhou, J., Huynh, Q. K., Hoffman, R. T., Crook, E. D., Daniels, M. C., Gulve, E. A., *et al.* (1998) Regulation of glutamine:fructose-6-phosphate amidotransferase by cAMP-dependent protein kinase. *Diabetes* **47**, 1836–1840
80. Hu, Y., Riesland, L., Paterson, A. J., and Kudlow, J. E. (2004) Phosphorylation of mouse glutamine-fructose-6-phosphate amidotransferase 2 (GFAT2) by cAMP-dependent protein kinase increases the enzyme activity. *J. Biol. Chem.* **279**, 29988–29993
81. Broschat, K. O., Gorka, C., Page, J. D., Martin-Berger, C. L., Davies, M. S., Huang, H., *et al.* (2002) Kinetic characterization of human glutamine-fructose-6-phosphate amidotransferase I. *J. Biol. Chem.* **277**, 14764–14770
82. Ruegenberg, S., Horn, M., Pichlo, C., Allmeroth, K., Baumann, U., and Denzel, M. S. (2020) Loss of GFAT-1 feedback regulation activates the hexosamine pathway that modulates protein homeostasis. *Nat. Commun.* **11**, 687



83. Campbell, S., Mesaros, C., Izzo, L., Affronti, H., Noji, M., Schaffer, B. E., *et al.* (2021) Glutamine deprivation triggers NAGK-dependent hexosamine salvage. *Elife* **10**, e62644
84. Lo, W.-Y., Yang, W.-K., Peng, C.-T., Pai, W.-Y., and Wang, H.-J. (2018) MicroRNA-200a/200b modulate high glucose-induced endothelial inflammation by targeting O-linked N-acetylglucosamine transferase expression. *Front. Physiol.* **9**, 355
85. Förster, L., Indra, D., Rosenberger, K., Zver, L., and Hofbauer, R. (2021) L-carnitine exerts a nutrigenomic effect via direct modulation of nuclear receptor signaling in adipocytes, hepatocytes and SKMC, demonstrating its nutritional impact. *Nutr. Res.* **85**, 84–98
86. Sodi, V. L., Khaku, S., Krutilina, R., Schwab, L. P., Vocadlo, D. J., Seagroves, T. N., *et al.* (2015) mTOR/MYC Axis regulates O-GlcNAc transferase expression and O-GlcNAcylation in breast cancer. *Mol. Cancer Res.* **13**, 923–933
87. Zhang, F., Snead, C. M., and Catravas, J. D. (2012) Hsp90 regulates O-linked  $\beta$ -N-acetylglucosamine transferase: a novel mechanism of modulation of protein O-linked  $\beta$ -N-acetylglucosamine modification in endothelial cells. *Am. J. Physiol. Cell Physiol.* **302**, C1786–C1796
88. Park, S., Pak, J., Jang, L., and Cho, J. (2014) Inhibition of mTOR affects protein stability of OGT. *Biochem. Biophys. Res. Commun.* **453**, 208–212
89. Seo, H. G., Kim, H. B., Kang, M. J., Ryum, J. H., Yi, E. C., and Cho, J. W. (2016) Identification of the nuclear localisation signal of O-GlcNAc transferase and its nuclear import regulation. *Sci. Rep.* **6**, 34614
90. Bullen, J. W., Balsbaugh, J. L., Chanda, D., Shabanowitz, J., Hunt, D. F., Neumann, D., *et al.* (2014) Cross-talk between two essential nutrient-sensitive enzymes. *J. Biol. Chem.* **289**, 10592–10606
91. Whelan, S. A., Lane, M. D., and Hart, G. W. (2008) Regulation of the O-linked  $\beta$ -N-acetylglucosamine transferase by insulin signaling. *J. Biol. Chem.* **283**, 21411–21417
92. Yang, X., Ongusaha, P. P., Miles, P. D., Havstad, J. C., Zhang, F., So, W. V., *et al.* (2008) Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. *Nature* **451**, 964–969
93. Kaasik, K., Kivimäe, S., Allen, J. J., Chalkley, R. J., Huang, Y., Baer, K., *et al.* (2013) Glucose sensor O-GlcNAcylation coordinates with phosphorylation to regulate circadian clock. *Cell Metab.* **17**, 291–302
94. Wang, Z., Pandey, A., and Hart, G. W. (2007) Dynamic interplay between O-linked N-Acetylglucosaminylation and glycogen synthase kinase-3-dependent phosphorylation. *Mol. Cell. Proteomics* **6**, 1365–1379
95. Huttlin, E. L., Jedrychowski, M. P., Elias, J. E., Goswami, T., Rad, R., Beausoleil, S. A., *et al.* (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. *Cell* **143**, 1174–1189
96. Ruan, H.-B., Ma, Y., Torres, S., Zhang, B., Feriod, C., Heck, R. M., *et al.* (2017) Calcium-dependent O-GlcNAc signaling drives liver autophagy in adaptation to starvation. *Genes Dev.* **31**, 1655–1665
97. Hornbeck, P. V., Zhang, B., Murray, B., Kornhauser, J. M., Latham, V., and Skrzypek, E. (2015) PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. *Nucleic Acids Res.* **43**, D512–520
98. Robles, M. S., Humphrey, S. J., and Mann, M. (2017) Phosphorylation is a central mechanism for circadian control of metabolism and physiology. *Cell Metab.* **25**, 118–127
99. Berthier, A., Vinod, M., Porez, G., Steenackers, A., Alexandre, J., Yamakawa, N., *et al.* (2018) Combinatorial regulation of hepatic cytoplasmic signaling and nuclear transcriptional events by the OGT/REV-ERB $\alpha$  complex. *Proc. Natl. Acad. Sci. U. S. A.* **115**, E11033–E11042
100. James, L. R., Ingram, A., Ly, H., Thai, K., Cai, L., and Scholey, J. W. (2001) Angiotensin II activates the GFAT promoter in mesangial cells. *Am. J. Physiol. Renal Physiol.* **281**, F151–F162
101. Lucena, M. C., Carvalho-Cruz, P., Donadio, J. L., Oliveira, I. A., de Queiroz, R. M., Marinho-Carvalho, M. M., *et al.* (2016) Epithelial Mesenchymal transition induces aberrant glycosylation through hexosamine biosynthetic pathway activation. *J. Biol. Chem.* **291**, 12917–12929
102. Shimizu, M., and Tanaka, N. (2019) IL-8-induced O-GlcNAc modification via GLUT3 and GFAT regulates cancer stem cell-like properties in colon and lung cancer cells. *Oncogene* **38**, 1520–1533
103. Wang, Z. V., Deng, Y., Gao, N., Pedrozo, Z., Li, D. L., Morales, C. R., *et al.* (2014) Spliced X-box binding protein 1 couples the unfolded protein response to hexosamine biosynthetic pathway. *Cell* **156**, 1179–1192
104. Manzari, B., Kudlow, J. E., Fardin, P., Merello, E., Ottaviano, C., Puppo, M., *et al.* (2007) Induction of macrophage glutamine: fructose-6-phosphate amidotransferase expression by hypoxia and by Picolinic acid. *Int. J. Immunopathol. Pharmacol.* **20**, 47–58
105. Al-Mukh, H., Baudoin, L., Bouaboud, A., Sanchez-Salgado, J.-L., Mar-qa, N., Khair, M., *et al.* (2020) Lipopolysaccharide induces GFAT2 expression to promote O-linked  $\beta$ -N-acetylglucosaminylation and attenuate inflammation in macrophages. *J. Immunol.* **205**, 2499–2510
106. Huang, H., Wang, Y., Huang, T., Wang, L., Liu, Y., Wu, Q., *et al.* (2021) FOXA2 inhibits doxorubicin-induced apoptosis via transcriptionally activating HBP rate-limiting enzyme GFPT1 in HCC cells. *J. Physiol. Biochem.* **77**, 625–638
107. Yamazaki, K., Mizui, Y., Oki, T., Okada, M., and Tanaka, I. (2000) Cloning and characterization of mouse glutamine:fructose-6-phosphate amidotransferase 2 gene promoter. *Gene* **261**, 329–336
108. Chao, D., Ariake, K., Sato, S., Ohtsuka, H., Takadate, T., Ishida, M., *et al.* (2021) Stomatin-like protein 2 induces metastasis by regulating the expression of a rate-limiting enzyme of the hexosamine biosynthetic pathway in pancreatic cancer. *Oncol. Rep.* **45**, 90
109. Xu, X., Qiao, D., Pan, L., Boldogh, I., Zhao, Y., and Brasier, A. R. (2022) RELA $\bullet$ Oxoguanine DNA glycosylase1 is an epigenetic regulatory complex coordinating the hexosamine biosynthetic pathway in RSV infection. *Cells* **11**, 2210
110. Maffei, B., Laverrière, M., Wu, Y., Triboulet, S., Perrinet, S., Duchateau, M., *et al.* (2020) Infection-driven activation of transglutaminase 2 boosts glucose uptake and hexosamine biosynthesis in epithelial cells. *EMBO J.* **39**, e102166
111. Groves, J. A., Maduka, A. O., O'Meally, R. N., Cole, R. N., and Zachara, N. E. (2017) Fatty acid synthase inhibits the O-GlcNAcase during oxidative stress. *J. Biol. Chem.* **292**, 6493–6511
112. Zeng, Q., Zhao, R.-X., Chen, J., Li, Y., Li, X.-D., Liu, X.-L., *et al.* (2016) O-linked GlcNAcylation elevated by HPV E6 mediates viral oncogenesis. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 9333–9338
113. Peng, K., Liu, R., Jia, C., Wang, Y., Jeong, G. H., Zhou, L., *et al.* (2021) Regulation of O-linked N-acetyl glucosamine transferase (OGT) through E6 stimulation of the ubiquitin ligase activity of E6AP. *Int. J. Mol. Sci.* **22**, 10286
114. Li, Z., Li, X., Nai, S., Geng, Q., Liao, J., Xu, X., *et al.* (2017) Checkpoint kinase 1-induced phosphorylation of O-linked  $\beta$ -N-acetylglucosamine transferase regulates the intermediate filament network during cytokinesis. *J. Biol. Chem.* **292**, 19548–19555
115. Wang, Y., Shu, H., Liu, J., Jin, X., Wang, L., Qu, Y., *et al.* (2022) EGF promotes PKM2 O-GlcNAcylation by stimulating O-GlcNAc transferase phosphorylation at Y976 and their subsequent association. *J. Biol. Chem.* **298**, 102340
116. Latorre-Muro, P., O'Malley, K. E., Bennett, C. F., Perry, E. A., Balsa, E., Tavares, C. D. J., *et al.* (2021) A cold-stress-inducible PERK/OGT axis controls TOM70-assisted mitochondrial protein import and cristae formation. *Cell Metab.* **33**, 598–614.e7
117. Song, M., Kim, H.-S., Park, J.-M., Kim, S.-H., Kim, I.-H., Ryu, S. H., *et al.* (2008) o-GlcNAc transferase is activated by CaMKIV-dependent phosphorylation under potassium chloride-induced depolarization in NG-108-15 cells. *Cell. Signal.* **20**, 94–104
118. Butkinaree, C., Cheung, W. D., Park, S., Park, K., Barber, M., and Hart, G. W. (2008) Characterization of  $\beta$ -N-acetylglucosaminidase cleavage by caspase-3 during apoptosis. *J. Biol. Chem.* **283**, 23557–23566
119. Lin, J., Xiang, Y., Huang, J., Zeng, H., Zeng, Y., Liu, J., *et al.* (2022) NAT10 maintains OGA mRNA stability through ac4C modification in regulating oocyte maturation. *Front. Endocrinol. (Lausanne)* **13**, 907286
120. Deng, X., Yi, X., Huang, D., Liu, P., Chen, L., Du, Y., *et al.* (2020) ROCK2 mediates osteosarcoma progression and TRAIL resistance by modulating O-GlcNAc transferase degradation. *Am. J. Cancer Res.* **10**, 781–798
121. Dey, A., Seshasayee, D., Noubade, R., French, D. M., Liu, J., Chaurushiya, M. S., *et al.* (2012) Loss of the tumor suppressor BAP1 causes myeloid transformation. *Science* **337**, 1541–1546

122. Li, C.-J., Li, D.-G., Liu, E.-J., and Jiang, G.-Z. (2023) Circ8199 encodes a protein that inhibits the activity of OGT by JAK2-STAT3 pathway in esophageal squamous cell carcinoma. *Am. J. Cancer Res.* **13**, 1107–1117
123. Sun, M.-X., An, H.-Y., Sun, Y.-B., Sun, Y.-B., and Bai, B. (2022) LncRNA EBLN3P attributes methotrexate resistance in osteosarcoma cells through miR-200a-3p/O-GlcNAc transferase pathway. *J. Orthop. Surg. Res.* **17**, 557
124. Wang, L., Feng, Y., Zhang, C., Chen, X., Huang, H., Li, W., *et al.* (2021) Upregulation of OGT by Caveolin-1 promotes hepatocellular carcinoma cell migration and invasion. *Cell Biol. Int.* **45**, 2251–2263
125. Huang, W., Chen, L., Zhu, K., and Wang, D. (2021) Oncogenic microRNA-181d binding to OGT contributes to resistance of ovarian cancer cells to cisplatin. *Cell Death Discov.* **7**, 379
126. Wang, N., Yu, M., Fu, Y., and Ma, Z. (2022) Blocking ATM attenuates SKOV3 cell proliferation and migration by disturbing OGT/OGA expression via hsa-miR-542-5p. *Front. Oncol.* **12**, 839508
127. Herzog, K., Bandiera, S., Pernet, S., Fauvelle, C., Jühling, F., Weiss, A., *et al.* (2020) Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity. *Gut* **69**, 380–392
128. Kalantzakos, T. J., Sullivan, T. B., Sebel, L. E., Canes, D., Burks, E. J., Moinzadeh, A., *et al.* (2021) MicroRNAs MiR-15a and MiR-26a cooperatively regulate O-GlcNAc-transferase to control proliferation in clear cell renal cell carcinoma. *Cancer Biomark.* **30**, 343–351
129. Kalantzakos, T. J., Sullivan, T. B., Gloria, T., Canes, D., Moinzadeh, A., and Rieger-Christ, K. M. (2021) MiRNA-424-5p suppresses proliferation, migration, and invasion of clear cell renal cell carcinoma and attenuates expression of O-GlcNAc-Transferase. *Cancers (Basel)* **13**, 5160
130. Ning, D., Chen, J., Du, P., Liu, Q., Cheng, Q., Li, X., *et al.* (2021) The crosstalk network of XIST/miR-424-5p/OGT mediates RAF1 glycosylation and participates in the progression of liver cancer. *Liver Int.* **41**, 1933–1944
131. Liu, X., Chen, X., Xiao, M., Zhu, Y., Gong, R., Liu, J., *et al.* (2021) RANBP2 activates O-GlcNAcylation through inducing CEBP $\alpha$ -dependent OGA downregulation to promote hepatocellular carcinoma Malignant Phenotypes. *Cancers (Basel)*. **13**, 3475
132. Vaidyanathan, K., Niranjana, T., Selvan, N., Teo, C. F., May, M., Patel, S., *et al.* (2017) Identification and characterization of a missense mutation in the O-linked  $\beta$ -N-acetylglucosamine (O-GlcNAc) transferase gene that segregates with X-linked intellectual disability. *J. Biol. Chem.* **292**, 8948–8963
133. Qian, K., Wang, S., Fu, M., Zhou, J., Singh, J. P., Li, M.-D., *et al.* (2018) Transcriptional regulation of O-GlcNAc homeostasis is disrupted in pancreatic cancer. *J. Biol. Chem.* **293**, 13989–14000
134. Lin, C.-H., Liao, C.-C., Chen, M.-Y., and Chou, T.-Y. (2021) Feedback regulation of O-GlcNAc transferase through translation control to maintain Intracellular O-GlcNAc homeostasis. *Int. J. Mol. Sci.* **22**, 3463
135. Jiang, M., Xu, B., Li, X., Shang, Y., Chu, Y., Wang, W., *et al.* (2019) O-GlcNAcylation promotes colorectal cancer metastasis via the miR-101-O-GlcNAc/EZH2 regulatory feedback circuit. *Oncogene* **38**, 301–316
136. Li, X., Zhang, Z., Li, L., Gong, W., Lazenby, A. J., Swanson, B. J., *et al.* (2017) Myeloid-derived cullin 3 promotes STAT3 phosphorylation by inhibiting OGT expression and protects against intestinal inflammation. *J. Exp. Med.* **214**, 1093–1109
137. Young, M. E., Yan, J., Razeghi, P., Cooksey, R. C., Guthrie, P. H., Stepkowski, S. M., *et al.* (2007) Proposed regulation of gene expression by glucose in Rodent heart. *Gene Regul. Syst. Bio.* **1**, 251–262
138. Muthusamy, S., DeMartino, A. M., Watson, L. J., Brittan, K. R., Zafir, A., Dassanayaka, S., *et al.* (2014) MicroRNA-539 is up-regulated in failing heart, and suppresses O-GlcNAcase expression. *J. Biol. Chem.* **289**, 29665–29676
139. Zhang, C., Lian, H., Xie, L., Yin, N., and Cui, Y. (2020) LncRNA ELFN1-AS1 promotes esophageal cancer progression by up-regulating GFPT1 via sponging miR-183-3p. *Biol. Chem.* **401**, 1053–1061
140. Liu, R., Ma, X., Chen, L., Yang, Y., Zeng, Y., Gao, J., *et al.* (2017) MicroRNA-15b suppresses Th17 differentiation and is associated with pathogenesis of multiple Sclerosis by targeting O-GlcNAc transferase. *J. Immunol.* **198**, 2626–2639
141. Yan, W., Cao, M., Ruan, X., Jiang, L., Lee, S., Lemanek, A., *et al.* (2022) Cancer-cell-secreted miR-122 suppresses O-GlcNAcylation to promote skeletal muscle proteolysis. *Nat. Cell Biol.* **24**, 793–804
142. Muthusamy, S., Hong, K. U., Dassanayaka, S., Hamid, T., and Jones, S. P. (2015) E2F1 transcription factor regulates O-linked N-acetylglucosamine (O-GlcNAc) transferase and O-GlcNAcase expression. *J. Biol. Chem.* **290**, 31013–31024
143. Belke, D. D. (2011) Swim-exercised mice show a decreased level of protein O-GlcNAcylation and expression of O-GlcNAc transferase in heart. *J. Appl. Physiol.* **111**, 157–162
144. Zhang, Z., Tan, E. P., VandenHull, N. J., Peterson, K. R., and Slawson, C. (2014) O-GlcNAcase expression is sensitive to changes in O-GlcNAc homeostasis. *Front. Endocrinol. (Lausanne)* **5**, 206
145. Park, S.-K., Zhou, X., Pendleton, K. E., Hunter, O. V., Kohler, J. J., O'Donnell, K. A., *et al.* (2017) A conserved splicing silencer dynamically regulates O-GlcNAc transferase intron retention and O-GlcNAc homeostasis. *Cell Rep.* **20**, 1088–1099
146. Wilkinson, M. J., Manoogian, E. N. C., Zadourian, A., Lo, H., Fakhouri, S., Shoghi, A., *et al.* (2020) Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome. *Cell Metab.* **31**, 92–104.e5
147. Kim, S., Kim, S. A., Han, J., and Kim, I.-S. (2021) Rho-kinase as a target for cancer therapy and its immunotherapeutic potential. *Int. J. Mol. Sci.* **22**, 12916
148. Kobriniski, D. A., Yang, H., and Kittaneh, M. (2020) BAP1: role in carcinogenesis and clinical implications. *Transl Lung Cancer Res.* **9**, S60–S66
149. Stephen, H. M., Adams, T. M., and Wells, L. (2021) Regulating the regulators: mechanisms of substrate selection of the O-GlcNAc cycling enzymes OGT and OGA. *Glycobiology* **31**, 724–733
150. King, D. T., Males, A., Davies, G. J., and Vocadlo, D. J. (2019) Molecular mechanisms regulating O-linked N-acetylglucosamine (O-GlcNAc)-processing enzymes. *Curr. Opin. Chem. Biol.* **53**, 131–144
151. Cheung, W. D., Sakabe, K., Housley, M. P., Dias, W. B., and Hart, G. W. (2008) O-linked  $\beta$ -N-acetylglucosaminyltransferase substrate specificity is regulated by myosin phosphatase targeting and other interacting proteins. *J. Biol. Chem.* **283**, 33935–33941
152. Jinek, M., Rehwinkel, J., Lazarus, B. D., Izaurralde, E., Hanover, J. A., and Conti, E. (2004) The superhelical TPR-repeat domain of O-linked GlcNAc transferase exhibits structural similarities to importin alpha. *Nat. Struct. Mol. Biol.* **11**, 1001–1007
153. Kohler, J. J. (2017) Carb cutting works better with a partner. *Nat. Struct. Mol. Biol.* **24**, 433–435
154. Elsen, N. L., Patel, S. B., Ford, R. E., Hall, D. L., Hess, F., Kandula, H., *et al.* (2017) Insights into activity and inhibition from the crystal structure of human O-GlcNAcase. *Nat. Chem. Biol.* **13**, 613–615
155. Joiner, C. M., Levine, Z. G., Aonbangkhen, C., Woo, C. M., and Walker, S. (2019) Aspartate residues far from the active site drive O-GlcNAc transferase substrate selection. *J. Am. Chem. Soc.* **141**, 12974–12978
156. Vocadlo, D. J. (2012) O-GlcNAc processing enzymes: catalytic mechanisms, substrate specificity, and enzyme regulation. *Curr. Opin. Chem. Biol.* **16**, 488–497
157. März, P., Stetefeld, J., Bendfeldt, K., Nitsch, C., Reinstein, J., Shoeman, R. L., *et al.* (2006) Ataxin-10 interacts with O-linked beta-N-acetylglucosamine transferase in the brain. *J. Biol. Chem.* **281**, 20263–20270
158. Levine, Z. G., and Walker, S. (2016) The Biochemistry of O-GlcNAc transferase: which functions Make it essential in mammalian cells? *Annu. Rev. Biochem.* **85**, 631–657
159. Stephen, H. M., Praissman, J. L., and Wells, L. (2021) Generation of an interactome for the tetratricopeptide repeat domain of O-GlcNAc transferase indicates a role for the enzyme in intellectual disability. *J. Proteome Res.* **20**, 1229–1242
160. Martin, J. C., Fadda, E., Ito, K., and Woods, R. J. (2014) Defining the structural origin of the substrate sequence independence of O-GlcNAcase using a combination of molecular docking and dynamics simulation. *Glycobiology* **24**, 85–96

161. Schimpl, M., Schüttelkopf, A. W., Borodkin, V. S., and van Aalten, D. M. F. (2010) Human OGA binds substrates in a conserved peptide recognition groove. *Biochem. J.* **432**, 1–7
162. Ruan, H.-B., Han, X., Li, M.-D., Singh, J. P., Qian, K., Azarhoush, S., *et al.* (2012) O-GlcNAc transferase/host cell factor C1 complex regulates gluconeogenesis by modulating PGC-1 $\alpha$  stability. *Cell Metab.* **16**, 226–237
163. Cheung, W. D., and Hart, G. W. (2008) AMP-activated protein kinase and p38 MAPK activate O-GlcNAcylation of neuronal proteins during glucose deprivation. *J. Biol. Chem.* **283**, 13009–13020
164. Whisenhunt, T. R., Yang, X., Bowe, D. B., Paterson, A. J., Van Tine, B. A., and Kudlow, J. E. (2006) Disrupting the enzyme complex regulating O-GlcNAcylation blocks signaling and development. *Glycobiology* **16**, 551–563
165. Lai, C.-Y., Liu, H., Tin, K. X., Huang, Y., Yeh, K.-H., Peng, H. W., *et al.* (2019) Identification of UAP1L1 as a critical factor for protein O-GlcNAcylation and cell proliferation in human hepatoma cells. *Oncogene* **38**, 317–331
166. Ito, R., Katsura, S., Shimada, H., Tsuchiya, H., Hada, M., Okumura, T., *et al.* (2014) TET3-OGT interaction increases the stability and the presence of OGT in chromatin. *Genes Cells* **19**, 52–65
167. Laarse, S. A. M., Leney, A. C., and Heck, A. J. R. (2018) Crosstalk between phosphorylation and O-GlcNAcylation: friend or foe. *FEBS J.* **285**, 3152–3167
168. Allison, D. F., Wamsley, J. J., Kumar, M., Li, D., Gray, L. G., Hart, G. W., *et al.* (2012) Modification of RelA by O-linked N-acetylglucosamine links glucose metabolism to NF- $\kappa$ B acetylation and transcription. *Proc. Natl. Acad. Sci. U. S. A.* **109**, 16888–16893
169. Ma, Z., Chalkley, R. J., and Vosseller, K. (2017) Hyper-O-GlcNAcylation activates nuclear factor  $\kappa$ -light-chain-enhancer of activated B cells (NF- $\kappa$ B) signaling through interplay with phosphorylation and acetylation. *J. Biol. Chem.* **292**, 9150–9163
170. Kronlage, M., Dewenter, M., Grosso, J., Fleming, T., Oehl, U., Lehmann, L. H., *et al.* (2019) O-GlcNAcylation of histone deacetylase 4 protects the diabetic heart from failure. *Circulation* **140**, 580–594
171. Fujiki, R., Hashiba, W., Sekine, H., Yokoyama, A., Chikanishi, T., Ito, S., *et al.* (2011) GlcNAcylation of histone H2B facilitates its mono-ubiquitination. *Nature* **480**, 557–560
172. Ruan, H.-B., Nie, Y., and Yang, X. (2013) Regulation of protein degradation by O-GlcNAcylation: crosstalk with ubiquitination. *Mol. Cell. Proteomics* **12**, 3489–3497
173. Li, M.-D., Ruan, H.-B., Hughes, M. E., Lee, J.-S., Singh, J. P., Jones, S. P., *et al.* (2013) O-GlcNAc signaling entrains the circadian clock by inhibiting BMAL1/CLOCK ubiquitination. *Cell Metab.* **17**, 303–310
174. Yao, H., Li, A., and Wang, M. (2015) Systematic analysis and prediction of *in Situ* Cross talk of O-GlcNAcylation and phosphorylation. *Biomed. Res. Int.* **2015**, 279823
175. Leney, A. C., El Atmioui, D., Wu, W., Ovaa, H., and Heck, A. J. R. (2017) Elucidating crosstalk mechanisms between phosphorylation and O-GlcNAcylation. *Proc. Natl. Acad. Sci. U. S. A.* **114**, E7255–E7261
176. Aulak, K. S., Barnes, J. W., Tian, L., Mellor, N. E., Haque, M. M., Willard, B., *et al.* (2020) Specific O-GlcNAc modification at Ser-615 modulates eNOS function. *Redox Biol.* **36**, 101625
177. Hortemo, K. H., Lunde, P. K., Anonsen, J. H., Kvaløy, H., Munkvik, M., Rehn, T. A., *et al.* (2016) Exercise training increases protein O-GlcNAcylation in rat skeletal muscle. *Physiol. Rep.* **4**, e12896
178. Park, J., Jung, S., Kim, S.-M., Park, I. Y., Bui, N. A., Hwang, G.-S., *et al.* (2021) Repeated hypoxia exposure induces cognitive dysfunction, brain inflammation, and amyloid $\beta$ /p-Tau accumulation through reduced brain O-GlcNAcylation in zebrafish. *J. Cereb. Blood Flow Metab.* **41**, 3111–3126
179. Kim, S.-M., Zhang, S., Park, J., Sung, H. J., Tran, T.-D. T., Chung, C., *et al.* (2021) REM sleep deprivation impairs learning and memory by decreasing brain O-GlcNAc cycling in mouse. *Neurotherapeutics* **18**, 2504–2517
180. Richards, A. M., Nicholls, M. G., Espiner, E. A., Ikram, H., Cullens, M., and Hinton, D. (1986) Diurnal patterns of blood pressure, heart rate and vasoactive hormones in normal man. *Clin. Exp. Hypertens. A* **8**, 153–166
181. Isobe, S., Ohashi, N., Ishigaki, S., Tsuji, T., Sakao, Y., Kato, A., *et al.* (2016) Augmented circadian rhythm of the intrarenal renin–angiotensin systems in anti-thymocyte serum nephritis rats. *Hypertens. Res.* **39**, 312–320
182. Tuomela, T., Viinikka, L., and Perheentupa, J. (1990) Epidermal growth factor in mice: changes during circadian and female reproductive cycles. *Acta Endocrinol. (Copenh)* **123**, 643–648
183. Haus, E., Haus, E., Dumitriu, L., Nicolau, G. Y., Bologa, S., and Sackett-Lundeen, L. (2001) Circadian rhythms of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), cortisol, and melatonin in women with breast cancer. *Chronobiol. Int.* **18**, 709–727
184. Vaghefi, S. S. E., Mousavi, F., Khaksari, M., Asadikaram, G., and Soltani, Z. (2021) Sex-related changes in circadian rhythm of inflammatory and oxidative stress Markers in CKD. *Iran. J. Kidney Dis.* **15**, 13
185. Yang, H., Yang, L.-T., Liu, J., Tang, S., Zhao, X., Wang, Q., *et al.* (2018) Circadian protein CLK suppresses transforming growth factor- $\beta$  expression in peripheral B cells of nurses with day-night shift rotation. *Am. J. Transl. Res.* **10**, 4331–4337
186. Zimmet, P., Alberti, K. G. M. M., Stern, N., Bilu, C., El-Osta, A., Einat, H., *et al.* (2019) The circadian syndrome: is the metabolic syndrome and much more. *J. Intern. Med.* **286**, 181–191
187. Kohsaka, A., Laposky, A. D., Ramsey, K. M., Estrada, C., Joshu, C., Kobayashi, Y., *et al.* (2007) High-fat diet disrupts behavioral and molecular circadian rhythms in mice. *Cell Metab.* **6**, 414–421
188. Eckel-Mahan, K. L., Patel, V. R., de Mateo, S., Orozco-Solis, R., Ceglia, N. J., Sahar, S., *et al.* (2013) Reprogramming of the circadian clock by nutritional challenge. *Cell* **155**, 1464–1478
189. Zhou, L., Zhang, Z., Nice, E., Huang, C., Zhang, W., and Tang, Y. (2022) Circadian rhythms and cancers: the intrinsic links and therapeutic potentials. *J. Hematol. Oncol.* **15**, 21
190. Rutters, F., and Nefs, G. (2022) Sleep and circadian rhythm disturbances in diabetes: a narrative review. *Diabetes Metab. Syndr. Obes.* **15**, 3627–3637
191. Shen, Y., Lv, Q., Xie, W., Gong, S., Zhuang, S., Liu, J., *et al.* (2023) Circadian disruption and sleep disorders in neurodegeneration. *Transl. Neurodegener.* **12**, 8
192. Horta, M. A. C., Thieme, N., Gao, Y., Burnum-Johnson, K. E., Nicora, C. D., Gritsenko, M. A., *et al.* (2019) Broad substrate-specific phosphorylation events are associated with the initial stage of plant cell wall recognition in *Neurospora crassa*. *Front. Microbiol.* **10**, 2317
193. Krahmer, J., Hindle, M., Perby, L. K., Mogensen, H. K., Nielsen, T. H., Halliday, K. J., *et al.* (2022) The circadian clock gene circuit controls protein and phosphoprotein rhythms in *Arabidopsis thaliana*. *Mol. Cell. Proteomics* **21**, 100172
194. Mauvoisin, D., Atger, F., Dayon, L., Núñez Galindo, A., Wang, J., Martin, E., *et al.* (2017) Circadian and feeding rhythms orchestrate the diurnal liver acetylome. *Cell Rep.* **20**, 1729–1743
195. Masri, S., Patel, V. R., Eckel-Mahan, K. L., Peleg, S., Forne, I., Ladurner, A. G., *et al.* (2013) Circadian acetylome reveals regulation of mitochondrial metabolic pathways. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 3339–3344
196. Szabó, Á., Papin, C., Cornu, D., Chélot, E., Lipinszki, Z., Udvardy, A., *et al.* (2018) Ubiquitylation dynamics of the clock cell proteome and TIMELESS during a circadian cycle. *Cell Rep.* **23**, 2273–2282
197. Mauvoisin, D., Wang, J., Jouffe, C., Martin, E., Atger, F., Waridel, P., *et al.* (2014) Circadian clock-dependent and -independent rhythmic proteomes implement distinct diurnal functions in mouse liver. *Proc. Natl. Acad. Sci. U. S. A.* **111**, 167–172
198. Hughes, M. E., DiTacchio, L., Hayes, K. R., Vollmers, C., Pulivarthy, S., Baggs, J. E., *et al.* (2009) Harmonics of circadian gene transcription in mammals. *PLoS Genet.* **5**, e1000442
199. Pizarro, A., Hayer, K., Lahens, N. F., and Hogenesch, J. B. (2013) CircDB: a database of mammalian circadian gene expression profiles. *Nucleic Acids Res.* **41**, D1009–1013
200. Pembroke, W. G., Babbs, A., Davies, K. E., Ponting, C. P., and Oliver, P. L. (2015) Temporal transcriptomics suggest that twin-peaking genes reset the clock. *Elife* **4**, e10518



201. Li, S., Shui, K., Zhang, Y., Lv, Y., Deng, W., Ullah, S., *et al.* (2017) CGDB: a database of circadian genes in eukaryotes. *Nucleic Acids Res.* **45**, D397–D403
202. Buel, S. M., Debopadhyaya, S., De los Santos, H., Edwards, K. M., David, A. M., Dao, U. H., *et al.* (2022) The PAICE suite reveals circadian posttranscriptional timing of noncoding RNAs and spliceosome components in *Mus musculus* macrophages. *G3 (Bethesda)* **12**, jkac176
203. Janich, P., Arpat, A. B., Castelo-Szekely, V., Lopes, M., and Gatfield, D. (2015) Ribosome profiling reveals the rhythmic liver transcriptome and circadian clock regulation by upstream open reading frames. *Genome Res.* **25**, 1848–1859
204. Du, N.-H., Arpat, A. B., De Matos, M., and Gatfield, D. (2014) MicroRNAs shape circadian hepatic gene expression on a transcriptome-wide scale. *Elife* **3**, e02510
205. Hughes, M. E., Hong, H.-K., Chong, J. L., Indacochea, A. A., Lee, S. S., Han, M., *et al.* (2012) Brain-specific rescue of Clock reveals system-driven transcriptional rhythms in peripheral tissue. *PLoS Genet.* **8**, e1002835
206. Kuintzle, R. C., Chow, E. S., Westby, T. N., Gvakharia, B. O., Giebultowicz, J. M., and Hendrix, D. A. (2017) Circadian deep sequencing reveals stress-response genes that adopt robust rhythmic expression during aging. *Nat. Commun.* **8**, 14529
207. Castellana, S., Biagini, T., Petrizelli, F., Cabibbo, A., Mazzocchi, G., and Mazza, T. (2022) RhythmicDB: a database of predicted Multi-Frequency rhythmic transcripts. *Front. Genet.* **13**, 882044
208. Negoro, H., Kanematsu, A., Doi, M., Suadicani, S. O., Matsuo, M., Imamura, M., *et al.* (2012) Involvement of urinary bladder Connexin43 and the circadian clock in coordination of diurnal micturition rhythm. *Nat. Commun.* **3**, 809
209. Haspel, J. A., Chettimada, S., Shaik, R. S., Chu, J.-H., Raby, B. A., Cernadas, M., *et al.* (2014) Circadian rhythm reprogramming during lung inflammation. *Nat. Commun.* **5**, 4753
210. Jouffe, C., Cretenet, G., Symul, L., Martin, E., Atger, F., Naef, F., *et al.* (2013) The circadian clock coordinates ribosome biogenesis. *PLoS Biol.* **11**, e1001455
211. Zhang, R., Lahens, N. F., Ballance, H. I., Hughes, M. E., and Hogenesch, J. B. (2014) A circadian gene expression atlas in mammals: implications for biology and medicine. *Proc. Natl. Acad. Sci. U. S. A.* **111**, 16219–16224
212. Kim, E. Y., Jeong, E. H., Park, S., Jeong, H.-J., Edery, I., and Cho, J. W. (2012) A role for O-GlcNAcylation in setting circadian clock speed. *Genes Dev.* **26**, 490–502
213. Terajima, H., Yoshitane, H., Ozaki, H., Suzuki, Y., Shimba, S., Kuroda, S., *et al.* (2017) ADAR1 catalyzes circadian A-to-I editing and regulates RNA rhythm. *Nat. Genet.* **49**, 146–151
214. Masri, S., Rigor, P., Cervantes, M., Ceglia, N., Sebastian, C., Xiao, C., *et al.* (2014) Partitioning circadian transcription by SIRT6 leads to segregated control of cellular metabolism. *Cell* **158**, 659–672
215. Yang, G., Chen, L., Grant, G. R., Paschos, G., Song, W.-L., Musiek, E. S., *et al.* (2016) Timing of expression of the core clock gene *Bmal1* influences its effects on aging and survival. *Sci. Transl. Med.* **8**, 324ra16
216. Atger, F., Gobet, C., Marquis, J., Martin, E., Wang, J., Weger, B., *et al.* (2015) Circadian and feeding rhythms differentially affect rhythmic mRNA transcription and translation in mouse liver. *Proc. Natl. Acad. Sci. U. S. A.* **112**, E6579–E6588
217. Cretenet, G., Le Clech, M., and Gachon, F. (2010) Circadian clock-coordinated 12 Hr period rhythmic activation of the IRE1 $\alpha$  pathway controls lipid metabolism in mouse liver. *Cell Metab.* **11**, 47–57
218. Shao, M., Shan, B., Liu, Y., Deng, Y., Yan, C., Wu, Y., *et al.* (2014) Hepatic IRE1 $\alpha$  regulates fasting-induced metabolic adaptive programs through the XBP1s–PPAR $\alpha$  axis signalling. *Nat. Commun.* **5**, 3528
219. Hong, S.-H., Kang, M., Lee, K.-S., and Yu, K. (2016) High fat diet-induced TGF- $\beta$ /Gbb signaling provokes insulin resistance through the tribbles expression. *Sci. Rep.* **6**, 30265
220. Cao, Y., Gao, X., Zhang, W., Zhang, G., Nguyen, A. K., Liu, X., *et al.* (2011) Dietary fiber enhances TGF- $\beta$  signaling and growth inhibition in the gut. *Am. J. Physiol. Gastrointest. Liver Physiol.* **301**, G156–G164
221. Bosch-Queralt, M., Cantuti-Castelvetri, L., Damkou, A., Schifferer, M., Schlepckow, K., Alexopoulos, I., *et al.* (2021) Diet-dependent regulation of TGF $\beta$  impairs reparative innate immune responses after demyelination. *Nat. Metab.* **3**, 211–227
222. Hermetet, F., Buffière, A., Aznague, A., Pais De Barros, J.-P., Bastie, J.-N., Delva, L., *et al.* (2019) High-fat diet disturbs lipid raft/TGF- $\beta$  signaling-mediated maintenance of hematopoietic stem cells in mouse marrow. *Nat. Commun.* **10**, 523
223. Rahman, S. A., Castanon-Cervantes, O., Scheer, F. A. J. L., Shea, S. A., Czeisler, C. A., Davidson, A. J., *et al.* (2015) Endogenous circadian regulation of pro-inflammatory cytokines and chemokines in the presence of bacterial lipopolysaccharide in humans. *Brain Behav. Immun.* **47**, 4–13
224. D'Esposito, V., Di Tolla, M. F., Lecce, M., Cavalli, F., Libutti, M., Misso, S., *et al.* (2022) Lifestyle and dietary habits affect plasma levels of specific cytokines in healthy subjects. *Front. Nutr.* **9**, 913176
225. Daultbaev, N., Herscovitch, K., Das, M., Chen, H., Bernier, J., Matouk, E., *et al.* (2015) Down-regulation of IL-8 by high-dose vitamin D is specific to hyperinflammatory macrophages and involves mechanisms beyond up-regulation of *DUSP1*: vitamin D suppresses IL-8 in hyperinflammatory MDM. *Br. J. Pharmacol.* **172**, 4757–4771
226. Allen, L. A., Schmidt, J. R., Thompson, C. T., Carlson, B. E., Beard, D. A., and Lombard, J. H. (2019) High salt diet impairs cerebral blood flow regulation via salt-induced angiotensin II suppression. *Microcirculation* **26**, e12518
227. Wolfrum, C., Asilmaz, E., Luca, E., Friedman, J. M., and Stoffel, M. (2004) *Foxa2* regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. *Nature* **432**, 1027–1032
228. Lee, J. H., and Sancar, A. (2011) Regulation of apoptosis by the circadian clock through NF- $\kappa$ B signaling. *Proc. Natl. Acad. Sci. U. S. A.* **108**, 12036–12041
229. Thapaliya, S., Wree, A., Povero, D., Inzaugarat, M. E., Berk, M., Dixon, L., *et al.* (2014) Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model. *Dig. Dis. Sci.* **59**, 1197–1206
230. Lakshmanan, M. R., Nepokroeff, C. M., and Porter, J. W. (1972) Control of the synthesis of fatty-acid Synthetase in rat liver by insulin, Glucagon, and Adenosine 3':5' cyclic Monophosphate. *Proc. Natl. Acad. Sci. U. S. A.* **69**, 3516–3519
231. Volpe, J. J., and Vagelos, P. R. (1974) Regulation of mammalian fatty-acid Synthetase. The roles of Carbohydrate and insulin. *Proc. Natl. Acad. Sci. U. S. A.* **71**, 889–893
232. Saito, T., Hirano, M., Ide, T., Ichiki, T., Koibuchi, N., Sunagawa, K., *et al.* (2013) Pivotal role of Rho-associated kinase 2 in generating the intrinsic circadian rhythm of vascular contractility. *Circulation* **127**, 104–114
233. Soliman, H., Nyamandi, V., Garcia-Patino, M., Varela, J. N., Bankar, G., Lin, G., *et al.* (2015) Partial deletion of ROCK2 protects mice from high-fat diet-induced cardiac insulin resistance and contractile dysfunction. *Am. J. Physiol. Heart Circ. Physiol.* **309**, H70–H81
234. Early, J. O., Menon, D., Wyse, C. A., Cervantes-Silva, M. P., Zaslona, Z., Carroll, R. G., *et al.* (2018) Circadian clock protein BMAL1 regulates IL-1 $\beta$  in macrophages via NRF2. *Proc. Natl. Acad. Sci. U. S. A.* **115**, E8460–E8468
235. Hansen, K. F., Sakamoto, K., and Obrietan, K. (2011) MicroRNAs: a potential interface between the circadian clock and human health. *Genome Med.* **3**, 10
236. Kura, B., Parikh, M., Slezak, J., and Pierce, G. N. (2019) The influence of diet on MicroRNAs that impact cardiovascular disease. *Molecules* **24**, 1509
237. Kang, T.-H., and Leem, S.-H. (2014) Modulation of ATR-mediated DNA damage checkpoint response by cryptochrome 1. *Nucleic Acids Res.* **42**, 4427–4434
238. Ünsal-Kaçmaz, K., Mullen, T. E., Kaufmann, W. K., and Sancar, A. (2005) Coupling of human circadian and cell cycles by the Timeless protein. *Mol. Cell. Biol.* **25**, 3109–3116
239. Bu, Y., Yoshida, A., Chitnis, N., Altman, B. J., Tameire, F., Oran, A., *et al.* (2018) A PERK–miR-211 axis suppresses circadian regulators and

- protein synthesis to promote cancer cell survival. *Nat. Cell Biol.* **20**, 104–115
240. Deldicque, L., Cani, P. D., Philp, A., Raymackers, J.-M., Meakin, P. J., Ashford, M. L. J., *et al.* (2010) The unfolded protein response is activated in skeletal muscle by high-fat feeding: potential role in the down-regulation of protein synthesis. *Am. J. Physiol. Endocrinol. Metab.* **299**, E695–E705
241. Tumanovska, L. V., Swanson, R. J., Serebrovska, Z. O., Portnichenko, G. V., Goncharov, S. V., Kysilov, B. A., *et al.* (2019) Cholesterol enriched diet suppresses ATF6 and PERK and upregulates the IRE1 pathways of the unfolded protein response in spontaneously hypertensive rats: Relevance to pathophysiology of atherosclerosis in the setting of hypertension. *Pathophysiology* **26**, 219–226
242. Manzella, N., Bracci, M., Strafella, E., Staffolani, S., Ciarapica, V., Copertaro, A., *et al.* (2015) Circadian modulation of 8-oxoguanine DNA damage repair. *Sci. Rep.* **5**, 13752
243. Komakula, S. S. B., Tumova, J., Kumaraswamy, D., Burchat, N., Vartanian, V., Ye, H., *et al.* (2018) The DNA repair protein OGG1 protects against obesity by altering mitochondrial energetics in white adipose tissue. *Sci. Rep.* **8**, 14886
244. Sampath, H., Vartanian, V., Rollins, M. R., Sakumi, K., Nakabeppu, Y., and Lloyd, R. S. (2012) 8-Oxoguanine DNA glycosylase (OGG1) deficiency increases susceptibility to obesity and metabolic dysfunction. *PLoS One* **7**, e51697
245. O-Sullivan, I., Zhang, W., Wasserman, D. H., Liew, C. W., Liu, J., Paik, J., *et al.* (2015) FoxO1 integrates direct and indirect effects of insulin on hepatic glucose production and glucose utilization. *Nat. Commun.* **6**, 7079
246. Carrano, A. C., Liu, Z., Dillin, A., and Hunter, T. (2009) A conserved ubiquitination pathway determines longevity in response to diet restriction. *Nature* **460**, 396–399
247. Pang, L., Dunterman, M., Xuan, W., Gonzalez, A., Lin, Y., Hsu, W.-H., *et al.* (2023) Circadian regulator CLOCK promotes tumor angiogenesis in glioblastoma. *Cell Rep.* **42**, 112127
248. Dimova, E. Y., Jakupovic, M., Kubaichuk, K., Mennerich, D., Chi, T. F., Tamanini, F., *et al.* (2019) The circadian clock protein CRY1 is a negative regulator of HIF-1 $\alpha$ . *iScience* **13**, 284–304
249. Suyama, K., Silagi, E. S., Choi, H., Sakabe, K., Mochida, J., Shapiro, I. M., *et al.* (2016) Circadian factors BMAL1 and ROR $\alpha$  control HIF-1 $\alpha$  transcriptional activity in nucleus pulposus cells: implications in maintenance of intervertebral disc health. *Oncotarget* **7**, 23056–23071
250. Vaughan, M. E., Wallace, M., Handzlik, M. K., Chan, A. B., Metallo, C. M., and Lamia, K. A. (2020) Cryptochromes Suppress HIF1 $\alpha$  in muscles. *iScience* **23**, 101338
251. Peek, C. B., Levine, D. C., Cedernaes, J., Taguchi, A., Kobayashi, Y., Tsai, S. J., *et al.* (2017) Circadian clock interaction with HIF1 $\alpha$  mediates oxygenic metabolism and anaerobic glycolysis in skeletal muscle. *Cell Metab.* **25**, 86–92
252. Gaspar, J. M., Mendes, N. F., Corrêa-da-Silva, F., Lima-Junior, J. C. D., Gaspar, R. C., Ropelle, E. R., *et al.* (2018) Downregulation of HIF complex in the hypothalamus exacerbates diet-induced obesity. *Brain Behav. Immun.* **73**, 550–561